US20020006621A1 - Non-invasive method for isolation and detection of fetal DNA - Google Patents

Non-invasive method for isolation and detection of fetal DNA Download PDF

Info

Publication number
US20020006621A1
US20020006621A1 US09/827,853 US82785301A US2002006621A1 US 20020006621 A1 US20020006621 A1 US 20020006621A1 US 82785301 A US82785301 A US 82785301A US 2002006621 A1 US2002006621 A1 US 2002006621A1
Authority
US
United States
Prior art keywords
fetal
cells
dna
sample
nucleated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/827,853
Inventor
Diana Bianchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020006621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Priority to US09/827,853 priority Critical patent/US20020006621A1/en
Publication of US20020006621A1 publication Critical patent/US20020006621A1/en
Priority to US10/113,177 priority patent/US20020137088A1/en
Priority to US10/374,705 priority patent/US20040018509A1/en
Priority to US11/051,982 priority patent/US20060051775A1/en
Priority to US11/283,500 priority patent/US20070015171A1/en
Priority to US12/008,549 priority patent/US20080182261A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Definitions

  • fetal cells Distinguishing fetal cells from maternal cells has not been successful for several reasons, including the small number of fetal cells in a maternal blood sample and the fact that morphological differences are slight (e.g., trophoblasts are the only fetal cells which can be distinguished from maternal cells by morphology alone).
  • the present invention is based, at least in part, on the discovery that fetal nucleated cells are present in the peripheral blood of a pregnant woman at a level which allows them to be useful in prenatal diagnostic methods.
  • the method of the present invention is non-invasive because a peripheral blood sample from pregnant women, not fetal blood, is used as the source of the fetal DNA.
  • the fetal DNA is derived from fetal nucleated cells present in the peripheral blood of a pregnant woman.
  • the method of the present invention can be used to assess fetal characteristics (e.g. fetal sex and chromosomal abnormalities) or can be used to diagnose whether a fetus has a prenatal disease at an early stage of the gestational period.
  • the non-invasive method of the present invention does not expose the fetus or mother to risks, e.g. infection, fetal injury, and miscarriage, associated with invasive methods such as amniocentesis.
  • the present invention pertains to a method of detecting the presence or absence of a fetal DNA sequence of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman.
  • the method involves obtaining a sample peripheral blood from a pregnant woman, treating the sample of peripheral blood such that the fetal DNA present in the fetal nucleated cells is made available for detection and detecting the presence or absence of the fetal DNA sequence of interest in the available fetal DNA.
  • the proportion of fetal nucleated cells present in the sample of peripheral blood can be increased forming a sample enriched in fetal nucleated cells prior to the detection step.
  • the fetal DNA sequence of interest can be detected by treating the peripheral blood sample such that fetal DNA present in the sample is made available for hybridization with a DNA probe and subsequently contacting the available fetal DNA with a DNA probe hybridizable to fetal DNA of interest under hybridization conditions.
  • the presence or absence of hybridization between the DNA probe and the fetal DNA of interest is detected as an indication of the presence or absence of the fetal DNA of interest.
  • the method of the present invention can be used to determine the sex of a fetus by contacting the peripheral blood sample from a woman pregnant with a fetus with a DNA probe hybridizable to fetal Y chromosomal DNA.
  • the presence of hybridization between the DNA probe and the fetal Y chromosomal DNA can be detected as an indication of a male fetus or the absence of hybridization can be detected as an indication of a female fetus.
  • the method of the present invention also may be used for diagnosing a disease in a fetus.
  • a sample of peripheral blood obtained from a woman pregnant with a fetus is contacted with DNA probe hybridizable to fetal DNA of interest associated with a disease under hybridization conditions.
  • the presence or absence of hybridization between the DNA probe and the fetal DNA of interest is detected as an indication of whether the fetus has the disease.
  • the method of the present invention further can be used to detect a chromosomal abnormality in a fetus such as a chromosomal aneuploidy, e.g., trisomy 13, trisomy 18, or trisomy 21.
  • a chromosomal abnormality in a fetus such as a chromosomal aneuploidy, e.g., trisomy 13, trisomy 18, or trisomy 21.
  • a sample of peripheral blood from the woman pregnant with a fetus is obtained.
  • the fetal nucleated cells are separated from the peripheral blood sample onto a solid support forming immobilized fetal nucleated material, e.g. metaphase or interphase nuclei.
  • the immobilized fetal nucleated material is contacted with a DNA probe hybridizable to chromosomal fetal DNA of interest under hybridization conditions.
  • the method of the present invention further can be used to determine whether a pregnancy is at risk. Fetal blood hemhorrages into the maternal blood system typically occur when a pregnancy is at risk increasing the number of fetal cells present in the maternal blood.
  • a peripheral blood sample can be obtained from a pregnant woman at a selected gestational age and the number of fetal cells present in the sample can be detected. This detected number of fetal cells can be compared to a known standard representative of the number of cells present at the selected gestational age during a normal pregnancy. The standard can be established by taking peripheral blood samples from a group of women at the selected gestational age believed to be having normal pregnancies.
  • FIG. 1 is a schematic representation of the method of the present invention by which fetal nucleated cells are isolated from maternal cells and DNA within the fetal cells is assessed for the occurrence of a particular fetal DNA sequence.
  • FIG. 2 is an autoradiograph of diluted male DNA amplified for 222 bp sequence.
  • Lane 1 reagent control
  • lane 2 ⁇ 174 molecular weight standard
  • lane 3 100 ng
  • lane 4 10 ng
  • lane 5 1 ng
  • lane 6 200 pcg
  • lane 7 10pcg
  • lane 8 1 pcg.
  • FIG. 3 is a composite autoradiograph of amplified patient DNA.
  • Lane 1 10 ng normal male; lane 2: 10 ng normal female; lane 3: reagent control; lane 4: ⁇ X174;
  • lane 5 sorted cells from patient 1 (male fetus);
  • lane 6 sorted cells from patient 2 (male fetus);
  • lane 7 sorted cells from patient 3 (female fetus);
  • lane 8 sorted cells from patient 6 (female fetus);
  • lane 9 sorted cells from patient 7 (male fetus);
  • lane 10 sorted cells from patient 8 (male fetus);
  • lane 11 sorted cells from patient 9 (female fetus);
  • lane 12 cord blood from female infant whose cells were prenatally sorted in lane 8.
  • FIG. 4 is a diagram demonstrating the detection of Y chromosomal DNA sequences at various points of gestation in women bearing male pregnancies.
  • FIGS. 5A, 5B, 5 C, 5 D, 5 E and 5 F are a series of histograms obtained when FITC-anti transferrin receptor was used to determine the presence of mononuclear cells in samples from non-pregnant females to which male cells have been added.
  • FIG. 6 is a composite autoradiograph of amplified male DNA detected in TfR cells when 10 2 -10 6 male cells are added to samples from non-pregnant females and in TfR ⁇ cells when 10 5 -10 6 male cells are added to samples, from non-pregnant females.
  • FIGS. 7A, 7B, 7 C, 7 D, 7 E, 7 F, 7 G and 7 H are a series of histograms obtained when anti HPCA-1 antibody was used to determine the presence of mononuclear cells in samples from nonpregnant females to which male cells have been added.
  • FIG. 8 is a photograph illustrating a fluorescent cell due to the positive results of in situ hybridization of the pDP97 probe for the Y chromosome to a fetal nucleated red blood cell.
  • FIG. 9 is a two-dimensional bivariate histogram depicting forward angle light scatter on the X axis (an indication of cell volume) and fluorescence intensity on the Y axis (a measure of cells binding the TfR antibody.
  • the TfR + cells respresenting 1.3% of the maternal mononuclear cells are encased in a box.
  • FIG. 10 is a photomicrograph of a flow-sorted interphase fetal nucleus isolated from maternal blood.
  • the single black dot represents hybridization to the Y chromosome and the three white dots represent hybridization to the chromosome 21s.
  • the karotype of this nucleus is 47, XY, +21.
  • the present invention relates to an in vitro method of separating or isolating fetal nucleated cells present in the blood of a pregnant woman (a maternal blood sample) from the pregnant woman's cells and of separating or isolating fetal DNA from maternal DNA. It further related to an in vitro method of prenatal detection and/or quantitation of selected fetal DNA in fetal DNA isolated from the maternal blood sample.
  • the method provides a noninvasive approach to detect and/or quantitate fetal DNA, such as that associated with a disease or a condition whose assessment during gestation is desired. It also provides a noninvasive means by which the sex of a fetus can be determined.
  • fetal nucleated cells are isolated from a maternal blood sample by means of a detectable material which binds to the fetal nucleated cells but not to maternal cells and is then separated from the maternal sample, resulting in separation of the fetal nucleated cells from the sample.
  • the fetal nucleated cells can be any undifferentiated hematopoietic cell and, particularly, fetal nucleated erythrocytes.
  • at least one detectably labelled monoclonal antibody specific for an antigen present on fetal nucleated cells, but not for an antigen present on maternal cells is combined with a maternal blood sample and, once bound to fetal nucleated cells, is separated from the maternal sample.
  • at least one detectably labelled monoclonal antibody specific for an antigen present on maternal cells, but not for an antigen present on fetal nucleated cells is used.
  • the two types of monoclonal antibodies are used.
  • the detectable label is a fluorescent molecule
  • separation is carried out by means of flow cytometry, in which fluorescently-labelled molecules are separated from unlabelled molecules.
  • fetal nucleated cells such as fetal nucleated erythrocytes
  • fetal DNA from maternal DNA. That this separation has occurred can be verified using known techniques, such as microscopy or detection of fetal hemoglobin.
  • the isolated fetal nucleated cells such as fetal nucleated erythrocytes, are treated to render DNA present in them available for amplification.
  • Amplification of DNA from fetal nucleated cells is carried out using a known amplification technique, such as the polymerase chain reaction (PCR).
  • Amplified fetal nucleated cell DNA is subsequently separated on the basis of size (e.g., by gel electrophoresis) and contacted with a selected labelled probe, such as labelled DNA complementary to a selected DNA sequence (e.g., complementary to an abnormal gene or gene portion, or Y-specific DNA). Detection of the labelled probe after it has hybridized to fetal DNA results in detection of the sequence of interest in the fetal DNA. Quantitation of the hybridized labelled probe results in quantitation of the fetal DNA.
  • a selected labelled probe such as labelled DNA complementary to a selected DNA sequence (e.g., complementary to an abnormal gene or gene portion, or Y-specific DNA).
  • a selected nucleic acid probe such as a labelled DNA probe for chromosomal DNA associated with a congenital abnormality
  • Detection and/or quantitation of the labelled probe after hybridization results in detection and/or quantitation of the fetal DNA to which the probe has hybridized.
  • fetal cells such as nucleated erythrocytes (also referred to as fetal NRBC), and other undifferentiated hematopoietic precursor cells, such as erythroblasts, lymphoblasts and myeloblasts, can be isolated or separated from maternal blood.
  • fetal cells such as nucleated erythrocytes (also referred to as fetal NRBC), and other undifferentiated hematopoietic precursor cells, such as erythroblasts, lymphoblasts and myeloblasts.
  • Fetal nucleated erythrocytes were particularly selected for sorting based on the following rationale:
  • the NRBC contain a full complement of fetal genes.
  • fetal nucleated erythrocytes can be isolated or separated from maternal blood and that DNA present in the isolated fetal cells can be used to assess fetal characteristics (e.g., sex, presence or absence of chromosomal abnormalities).
  • fetal nucleated erythroblasts have been shown to be present in blood obtained from pregnant women, thus making maternal blood a useful/reliable potential source of fetal DNA; fetal nucleated cells have been distinguished from maternal cells on the basis of surface antigenic characteristics, thus making it possible to separate the two cell types from one another; and fetal DNA present in the separated fetal nucleated cells has been analyzed and characterized.
  • One of the first steps in developing the present method of isolating fetal nucleated cells from the maternal blood supply was identification of monoclonal antibodies that permit identification and separation of fetal cells from maternal cells present in blood obtained from a pregnant woman. This has been done, as described in detail in the Examples. As a result, it has been determined that monoclonal antibodies which recognize maternal leucocytes and monoclonal antibodies which recognize fetal cell surface antigens are useful in separating maternal and fetal cells. The following is a brief description of monoclonal antibodies which have been shown to be useful in separating fetal nucleated cells from maternal cells present in a maternal blood sample. However, other monoclonal antibodies which distinguish between fetal and maternal cells on the basis of surface antigenic differences, can also be used in the present method.
  • the present method requires the use of at least one type of antibody which is specific for (or recognizes) a surface antigen present on fetal nucleated cells, for a surface antigen present on maternal cells, but not specific for both. That is, the present method can be carried out using one or more antibody which distinguishes fetal nucleated cells from maternal cells. The present method can be carried out using whole blood or blood treated or processed to enrich for (increase the concentration of) fetal nucleated cells.
  • monoclonal antibodies which distinguish fetal nucleated erythrocytes from maternal cells. It is to be understood, however, that in a similar manner, monoclonal antibodies which make it possible to select for another fetal nucleated cell type (or types) can be identified and used in the present method to separate fetal nucleated cell types from maternal cells (and, thus, fetal DNA sources from maternal DNA).
  • HLe-1 Becton-Dickinson Monoclonal center, Mountain View, Calif., catalog #7463
  • FITC fluorescein isothiocyanate
  • Example 1 As is also described (Example 1), a combination of monoclonal antibodies has been used for the same purpose (i.e., elimination of maternal cells from the blood sample). As described, anti-monocyte antibody (M3) and anti-lymphocytes antibody (L4) have been used to remove maternal cells from the mononuclear cell layer resulting from density gradient centrifugation.
  • M3 monoclonal antibodies
  • L4 anti-lymphocytes antibody
  • Monoclonal antibodies which recognize fetal nucleated cells but do not recognize maternal cells were also identified. As described in detail in Example 1, a monoclonal antibody which recognizes the transferrin receptor was identified. Erythroblasts have been shown to express the transferrin receptor (Loken, M. R., et al., Blood, 69:255-263 (1987)) antigen on their cell surfaces from the BFU-E stage until nuclear extrusion (Loken, M. R. et al., Blood, 69:255-263 (1987)). The transferrin receptor is also present on activated lymphocytes (Trowbridge, I. S. and M. B. Omary, Proc. Natl. Acad. Sci. USA.
  • tumor cells Greaves, M. et al., Int. J. Immunopharmac., 3:283-300 (1981)
  • trophoblast cells Galbraith, G. M. P. et al, Blood, 55:240-242 (1980)
  • TfR transferrin receptor
  • the antibody is not specific for fetal nucleated erythrocytes, it facilitated their enrichment in the flow-sorted samples.
  • Other monoclonal antibodies which are able to distinguish between fetal nucleated cells and maternal cells present in a blood sample can also be used.
  • Such antibodies include commercially available monoclonal antibodies and those which can be produced using known techniques.
  • Separation of fetal nucleated cells from a maternal blood sample using antibodies described above can be carried out with samples of whole blood or a fraction of whole blood (i.e., one resulting from treatment or processing of whole blood to increase the proportion of fetal nucleated cells present), referred to as an enriched maternal sample.
  • An enriched maternal sample is produced, for example, in a two-step process. The maternal sample is subjected to initial separation on the basis of size, such as by Ficoll-Hypaque density gradient centrifugation.
  • a supernatant layer which contains platelets; a mononuclear cell layer; and an agglutinated pellet which contains non-nucleated erythrocytes and granulocytes.
  • the mononuclear layer is separated from the other layers, to produce a maternal sample which is enriched in fetal nucleated cells.
  • the maternal sample is subjected to separation, based on surface antigenic differences between fetal nucleated cells and maternal cells using antibodies described above.
  • the maternal sample is contacted with at least one monoclonal antibody which is specific for either fetal nucleated cells or maternal cells, but not for both and, thus, makes it possible to separate the two types of cells.
  • the maternal sample can be combined with a set of two or more monoclonal antibodies, each of which is specific for either fetal or maternal cells, but not for both.
  • the combination of monoclonal antibodies can be designed to enhance separation of the two types of cells (e.g., the combination of anti-TfR antibody and HLe-1 antibody described previously) beyond that possible with a single monoclonal antibody. Separation of the fetal cells is carried out using known techniques, such as flow cytometry, use of immunomagnetic beads and cell panning.
  • the monoclonal antibodies have a detectable label (e.g., radioactive material, fluorophore).
  • fetal nucleated cells persisting from a previous pregnancy may be present in the peripheral blood sample. Steps may be taken to eliminate or significantly reduce the number of such residual nucleated cells if found to be present.
  • a type of fetal nucleated cell known to be associated with the present pregnancy may be selected for detection obviating any potential interference or contamination of the detection method by the residual fetal nucleated cells.
  • fetal nucleated cell type having a relatively short life span may be selected for detection ensuring the fetal nucleated cell is not from a previous pregnancy.
  • Fetal nucleated erythrocytes typically have a life span of about three months in the maternal circulation. The above-identified steps can be conducted using monoclonal antibodies which recognize antigens on the respective cells.
  • FIG. 1 An embodiment of the method of the present invention by which fetal cells are isolated and fetal DNA is detected is represented schematically in FIG. 1.
  • a maternal blood sample typically 20 ml.
  • the sample is separated into component layers on the basis of size and the mononuclear cell layer, referred to as the maternal sample enriched in nucleated cells (or enriched maternal sample), is removed for further processing.
  • the enriched maternal sample is contacted with at least one monoclonal antibody, as described above, and the resulting fetal nucleated cell/antibody complexes are separated using known methods (e.g., flow cytometry, immunomagnetic beads, cell panning).
  • Fetal DNA is crudely extracted from the resulting complexes (e.g., by heat), thus rendering it available for hybridization with nucleic acid probes.
  • Fetal DNA can be analyzed for a selected DNA sequence or DNA sequences, using known techniques. Prior to analysis, fetal DNA can be amplified, as needed, using known methods (e.g., PCR).
  • the sorted samples are amplified for an appropriate number of cycles of denaturation and annealing (e.g., approximately 24-60).
  • Control samples include a tube without added DNA to monitor for false positive amplification.
  • more than one separate fetal gene can be amplified simultaneously.
  • This technique known as “multiplex” amplification, has been used with six sets of primers in the diagnosis of DMD (Chamberlain, J. S., et al., Prenat. Diagnosis, : 349-355 (1989)).
  • the resulting amplification product is a mixture which contains amplified fetal DNA of interest (i.e., the DNA whose occurrence is to be detected and/or quantitated) and other DNA sequences.
  • amplified fetal DNA of interest and other DNA sequences are separated, using known techniques.
  • Subsequent analysis of amplified DNA can be carried out using known techniques, such as: digestion with restriction endonuclease, ultraviolet light visualization of ethidium bromide stained agarose gels, DNA sequencing, or hybridization with allele specific oligonucleotide probes (Saiki, R. K., et al, Am. J. Hum. Genet., 43 (Suppl):A35 (1988)).
  • the amplification mixture is separated on the basis of size and the resulting size-separated fetal DNA is contacted with an appropriate selected DNA probe or probes (DNA sufficiently complementary to the fetal DNA of interest that it hybridizes to the fetal DNA of interest under the conditions used).
  • the DNA probes are labelled (e.g., with a radioactive material, a fluorophore or other detectable material).
  • fetal DNA/labelled DNA probe complex is detected and/or quantitated (e.g., by autoradiography, detection of the fluorescent label).
  • the quantity of labelled complex (and, thus, of fetal DNA) can be determined by comparison with a standard curve (i.e., a predetermined relationship between quantity of label detected and a given reading).
  • the present method has been used to identify Y-specific DNA in nucleated erythrocytes obtained from peripheral blood of pregnant women. This is described in Example 4. Briefly, candidate fetal cells from blood samples obtained from 19 pregnant women were isolated by flow sorting. The DNA in these cells was amplified for a 222 base pair (bp) sequence present on the short arm of the Y chromosome as proof that the cells were derived from the fetus. The amplified DNA was compared with standardized DNA concentrations; 0.1 to 1 ng fetal DNA was obtained in the 20 ml maternal samples.
  • bp base pair
  • a 222 bp band of amplified DNA was detected, consistent with the presence of male DNA in the isolated cells; 6/7 of these were confirmed as male pregnancies by karyotyping amniocytes.
  • DNA prepared from cord blood at delivery also showed the presence of the Y chromosomal sequence.
  • the fetuses were female.
  • the Y chromosmal sequence was successfully detected in 75% of the male-bearing pregnancies, demonstrating for the first time that it is possible to isolate fetal gene sequences from maternal blood.
  • the cells that displayed green fluorescence, but not red fluorescence were fetal nucleated cells and were separated from the remainder of the sample. These cells were lysed, after which the DNA was amplified and probed for the presence of a 397 bp sequence of the Y chromosome.
  • Example 6 The results presented in Example 6 indicate the procedure allows the detection of the 397 bp sequence present in as little as 5 pg of male DNA. In addition, they suggest that there is a relationship between gestational age and detection of male DNA, as illustrated in FIG. 4. This data suggests there may be a biologic “window” for transfer of fetal nucleated erythrocytes into maternal circulation.
  • the present method also has been used to distinguish female fetal DNA from maternal DNA.
  • the two types of female DNA were distinguished using amplification of paternal polymorphism, as described in detail in Example 7. Briefly, venous blood samples were collected from women with uncomplicated pregnancies. Separation of fetal nucleated cells was conducted using Ficoll/Hypaque density centrifugation, followed by incubation with monoclonal antibodies (anti-TfR, anti-Leu 4 and anti-Leu M3) conjugated with a fluorescent marker (fluorescein, phycoerthyrin) and dual color analysis and flow sorting on a fluorescence-activated cell sorter.
  • monoclonal antibodies anti-TfR, anti-Leu 4 and anti-Leu M3
  • fluorescent marker fluorescein, phycoerthyrin
  • the cord blood contains a large percentage of nucleated erythrocytes.
  • the results obtained from these experiments were substantially similar to those obtained from pregnant women at various stages in gestation. Amplified sequences from the Y chromosome, consistent with the presence of male DNA, were detected when 10 2 male cells were added to the female cells.
  • Example 10 describes the procedure in detail. Briefly, venous blood samples are collected from pregnant women. The mononuclear cell layer is isolated by Ficoll/Hypaque density centrifugation and incubated with monoclonal antibodies which are conjugated with a fluorescent marker and directed against antigens on the surface of hematopoietic progenitor cells (see Example 11 for discussion of antibodies). Fluorescent cells, separated by flow sorting, have bound antibody recognizing primitive cell surface antigens, and thus, are hematopoietic precursor cells.
  • telomeres After the cells are lysed by boiling, they are subjected to polymerase chain reaction (PCR) amplification using primers selected to amplify a 397 base pair sequence from the Y chromosome. This method was used to study twenty-five women, eleven of whom have confirmed male pregnancies. In eight of these eleven women (77%), male DNA was detected in sorted cells which showed a positive response to a human progenitor cell antigen, thus, indicating that the cells were undifferentiated hematopoietic stem cells. This experiment confirms that fetal hematopoietic stem cells are circulating in the mother's blood.
  • PCR polymerase chain reaction
  • Example 12 As described in Example 12, the present method has been used to analyze venous blood from healthy pregnant women for the presence or absence of Y chromosomal DNA sequences and has been shown to be highly accurate in its ability to do so, as well as to distinguish between samples from women carrying male fetuses and women carrying female fetuses.
  • the only possible source of Y chromosomal DNA in maternal blood is male fetal cells (male cells carrying an X and a Y chromosome and female cells carry two X chromosomes).
  • CD36 which recognizes a cell surface antigen on nucleated erythrocytes and monocytes and glycophorin A, which recognizes an antigen present on erythrocytes.
  • the antibodies were conjugated, directly or indirectly, to a fluorescent dye. Fluorescent cells in the venous sample which bound one or both antibodies were flow sorted and later amplified for Y chromosomal sequences using PCR. Of the 18 women studied, 11 had male fetuses and 7 had female fetuses.
  • Y chromosomal DNA sequences were detected in cells sorted with CD36 and/or glycophorin A antibodies in 10 of the 11 (91%) women with male fetuses and in none of the 7 women bearing females. These results demonstrate that these two antibodies are particularly effective in identifying fetal nucleated cells in maternal blood.
  • fetal DNA can be obtained from fetal nucleated cells present in a maternal blood sample.
  • the method of detecting and/or quantitating fetal DNA which is represented in FIG. 1 is useful as a tool for prenatal assessment (e.g., as a means for assessing chromosomal abnormalities, for determining whether DNA associated with a disease is present, or for detecting Y-specific DNA). It is particularly useful because it is noninvasive and requires only a small sample of blood.
  • Fetal DNA sequences in fetal nucleated erythrocytes isolated as described herein or by other means by which fetal nucleated cells can be separated from a maternal blood sample, can be analyzed or assessed for the occurrence of a DNA sequence or DNA sequences (gene(s) or gene portion(s)) which are of interest for diagnostic or other purposes.
  • the DNA sequence(s) or gene(s)/gene portion(s) present in fetal cells are referred to herein as fetal DNA of interest.
  • the selected DNA whose presence or absence is to be determined and whose quantity can also be determined is the gene for a disease, such as cystic fibrosis, where the causative gene or gene portion has been cloned and sequenced; alternatively, it is a probe for X- or Y-specific DNA.
  • a disease such as cystic fibrosis
  • the causative gene or gene portion has been cloned and sequenced; alternatively, it is a probe for X- or Y-specific DNA.
  • appropriate modifications e.g., an appropriate DNA probe, time, temperature
  • a maternal blood sample typically 20 ml.
  • component layers based on relative weights (e.g., by Ficoll-Hypaque density gradient centrifugation) to remove non-nucleated erythrocytes and produce a mononuclear cell layer.
  • the mononuclear cell layer is stained with at least one appropriate monoclonal antibody (e.g., one which is specific for the type of fetal nucleated cell to be separated from the sample).
  • a monoclonal antibody specific for fetal nucleated cells such as anti-TfR antibody, described above, can be used.
  • the monoclonal antibody used bears a detectable label.
  • a combination of selected labelled monoclonal antibodies, such as monoclonal antibodies specific for fetal nucleated cells (e.g., anti-TfR antibody) and monoclonal antibodies specific for maternal leucocytes (Hle-1 or L4 and M3), each labelled with a different fluorescent compound, can be used to remove essentially all maternal cells. Labelled cells are subsequently separated from one another using a known method, such as flow cytometry.
  • Binding of the monoclonal antibodies to cells for which they are specific results in production of labelled monoclonal antibody-cell complexes.
  • fetal nucleated erythrocytes are bound by anti-TfR antibody, to produce fetal nucleated erythrocytes/anti-TfR antibody complexes, and maternal leucocytes are bound by HLe-1 antibody complexes.
  • the fetal nucleated erythrocyte/anti-TfR antibody complexes are separated from maternal cell/HLe-1 antibody complexes, using, for example, flow cytometry.
  • the fetal cells are lysed, to produce crudely extracted fetal DNA which is subsequently amplified, using, for example, PCR. This results in production of amplified fetal DNA, which is subsequently separated on the basis of size. Size-separated fetal DNA is contacted with labelled DNA probes (i.e., in prenatal detection of cystic fibrosis, a labelled DNA probe complementary to the gene associated with cystic fibrosis). If the fetal DNA contains DNA of interest (in this case, the gene associated with cystic fibrosis), fetal DNA of interest/labelled probe complexes are formed.
  • labelled DNA probes i.e., in prenatal detection of cystic fibrosis, a labelled DNA probe complementary to the gene associated with cystic fibrosis.
  • Fetal DNA of interest/labelled probe complexes are subsequently detected, using a known technique, such as autoradiography. Simple presence or absence of labelled fetal DNA of interest can be determined or the quantity of fetal DNA of interest can be determined. In either case, the result is assessment of fetal DNA obtained from a maternal blood sample for selected DNA.
  • fetal DNA associated with diseases or conditions other than cystic fibrosis can also be detected and/or quantitated by the present method.
  • an appropriate probe is used to detect the sequence of interest. For example, sequences from probes St14 (Oberle, I., et al., New Engl. J. Med., 312:682-686 (1985)), 49a (Guerin, P., et al., Nucleic Acids Res., 16:7759 (1988)), KM-19 (Gasparini, P., et al., Prenat.
  • St14 is a highly polymorphic sequence isolated from the long arm of the X chromosome that has potential usefulness in distinguishing female DNA from maternal DNA. It maps near the gene for Factor VIII:C and, thus, may also be utilized for prenatal diagnosis of Hemophilia A.
  • the maternal cells are depleted prior to fetal cell sorting.
  • the mononuclear cell layer is initially isolated from the blood of pregnant women by Ficoll-Hypaque centrifugation.
  • the resulting cell suspension consists predominantly of maternal cells; in order to enrich the eventual proportion of fetal cells present, the maternal cells are selectively removed by incubating the cells with antibodies attached to a solid support.
  • Such supports include magnetic beads, plastic flasks, plastic dishes and columns.
  • the antibodies bind antigens present on the cell surface of mature leukocytes.
  • the total number of cells remaining in the cell suspension is smaller, but the proportion of fetal cells present is larger.
  • the mononuclear cell layer is isolated, as described previously. This layer is then mixed with antibody-coated polymer particles containing magnetic cores (e.g., “Dynabeads”). These immunomagnetic beads are available coated with a variety of antibodies. For example, immunomagnetic beads coated with antibody to leucocyte antigens and antibody to mouse immunoglobulins, which can be subsequently conjugated to mouse monoclonal antibody against the human transferrin receptor, can be used. After mixing, the rosetted cells are isolated with a magnetic particle concentrator. In one embodiment, two sets of antibody-coated immunomagnetic beads are used in succession. First, the maternal leucocytes are depleted and then the remaining TfR positive cells are collected. Subsequent steps in the method (amplification, separation, contact with an appropriate DNA probe or probe set) are as described for cells separated by flow cytometry.
  • amplification, separation, contact with an appropriate DNA probe or probe set are as described for cells separated by flow cytometry.
  • the blood from the pregnant women was collected into tubes containing 10 IU of lithium perm1 of whole blood, diluted 1:10 with RPMI containing lithium, and incubated with the antibody coated beads at 4° C. overnight.
  • the desired cells were bound to the antibody on the bead; the beads collected by means of a cobalt-samarium magnet.
  • the antibody was directed against trophoblast antigens a similar technique can be utilized with, for example, antibody to cell surface antigens present on fetal nucleated erythrocytes and not present on maternal cells.
  • An advantage to this particular technique is that an initial step which results in mononuclear cell isolation is not added.
  • the magnetic beads can be used for both positive (fetal cells)and negative (maternal cells) selection.
  • An alternative method of isolation can be a modification of the method described by R. J. Berenson et al. ( J. of Immunol. Methods, 91(1986)) in which the high affinity between the protein avidin and the vitamin biotin was exploited to create an indirect immuno-adsorptive procedure.
  • avidin was linked to cyanogen bromide activated sepahrose 6MB beads and washed in an alternating fashion with coupling buffer (0.1 M NaHCO 3 in 0.5 M NaCl at pH 8.3). and washing buffer (0.1 M sodium acetate in 0.5 M NaCl at pH 4.5) and stored at 4° C.
  • the blood cells were incubated with 1) murine monoclonal antibody, and 2) biotinylated goat anti-mouse immunoglobulin.
  • a 3 ml column of gel was packed in Pharmacia K 19/15 column.
  • the treated cells were passed through the column in phosphate buffered saline containing 2% bovine serum albumin.
  • Adherent cells were dislodged by mechanical agitation. This technique can be applied to fetal cell separation if the antibodies used recognize fetal cell surface antigens or maternal cell surface antigens, but not both. Variation in methods for conjugating antibodies to beads exist; examples include those described by Thomas and co-workers (Thomas, T. E., et al. ( J. of Immuno.
  • Another alternative to mononuclear cell isolation is to selectively lyse maternal non-nucleated erythrocytes.
  • a number of buffers including 0.17M NH 4 Cl, 0.01M Tris, pH 7.3, have been described in the literature and are well known in isolation of hematopoietic stem cells for bone marrow transplantation.
  • Other buffers (“Lyse and Fix”, GenTrak) are available commercially.
  • the fetal cells may be cultured to increase the numbers of cells available for diagnosis, if desired.
  • E. Fibach et al. ( Blood, 73:100-103 (1989)) have described a method that supports the growth of human hematopoietic progenitor cells. This step-wise method involves 1) initial culture in the presence of conditioned medium from human bladder carcinoma cells, 2) removal of leucocytes by harvest of non-adherent cells and lysis with monoclonal antibodies and 3) reculture of cells in medium supplemented by recombinant erythropoietin.
  • a kit for use in carrying out the present method of isolating and detecting fetal DNA of interest, such as a chromosomal abnormality associated with a disease or other condition, in a maternal blood sample can be produced. It includes, for example, a container for holding the reagents needed; the reagents and, optionally, a solid support for use in separating fetal nucleated cell/specific antibody complexes from other sample components or for removing maternal cells complexed with a specific antibody.
  • reagents in a kit to be used in detecting fetal DNA of interest after amplification of fetal DNA by PCR can include: 1) at least one antibody specific for a surface antigen characteristic of fetal nucleated cells but not specific for a surface antigen characteristic of maternal leucocytes; selected DNA primers for use in amplifying fetal DNA by PCR; and at least one DNA probe complementary to the fetal DNA to be detected (fetal DNA of interest).
  • the kit can also include a solid support to be used in separating complexes formed from other samples components.
  • Such solid support can be, for example, a glass slide, nitrocellulose filter, or immunomagnetic beads and can have affixed thereto an antibody selective for the antibody present in the fetal nucleated cell/specific antibody complexes.
  • the technique of fetal NRBC isolation began with an initial Ficoll-Hypaque density gradient centrifugation to remove the tremendously high number of non-nucleated erythrocytes in maternal blood.
  • Peripheral blood was centrifuged and separated into a supernatant layer containing platelets, a mononuclear cell layer, and an agglutinated pellet consisting of non-nucleated erythrocytes and granulocytes.
  • the mononuclear cell layer consisted of lymphocytes, monocytes, possible trophoblasts, and, due to their increased size and density, NRBCs and some reticulocytes. While the Ficoll-Hypaque centrifugation represented an initial enrichment in the proportion of fetal NRBCs present in the maternal sample, flow cytometry and cell sorting was used to improve the purity of the isolated cell population.
  • HLe-1 positive and HLe-1 NEGATIVE fluorescent and non-fluorescent cell populations were sorted for detailed microscopy after Wright-Giemsh staining. While the HLe-1 positive populations were always composed of leucocytes independent of the sample source, the HLe-1 negative populations differed.
  • cord blood the HLe-1 negative cells were nonnucleated and nucleated erythrocytes with occasional platelets.
  • platelets In the pregnant women, there were platelets, non-nucleated erythrocytes, and a very rare NRBC. In non-pregnant adults, only platelets and debris were seen.
  • cord blood with it high percentage of NRBCS, was used as a reference to establish cell sorting parameters. Microscopy confirmed the specificity of the antibody-antigen binding and that the sorted HLe-1 negative cells were relatively free from leucocyte contamination. These sorting parameters were utilized to isolate potential fetal NRBC on 40 pregnancies.
  • the transferrin receptor (Newman, R., et al., Trends Biochem. Sci. 1:397-399 (1982)) is a surface glycoprotein important in cellular iron transport.
  • the TfR is present on activated lymphocytes (Trowbridge, I. S., et al., Proc. Natl. Acad. Sci. USA, 7:3039-3043 (1981)), certain tumor cells (Greaves, M. et al., Int. J. Immunopharmac., 3:283-300 (1981)), and trophoblast cells (Galbraith, G. M. P., et al., Blood, 55:240-242 (1980)).
  • TfR Erythroblasts express the TfR on their cell surfaces from the BFU-E stage until nuclear extrusion (Loken, M. R., et al., Blood, 69:255-263 (1987)).
  • TfR is an excellent “candidate antigen” for enrichment of fetal NRBCs found in maternal blood.
  • Monoclonal antibody against TfR is available as both a fluorescein conjugate (Becton-Dickinson catalog #7513) and a phycoerythrin (PR) conjugate (gift of Dr. Michael Loken, Becton-Dickinson).
  • the mononuclear cell layer was isolated from peripheral blood samples in 6 pregnant women, 4 non-pregnant adults, and 3 newborn umbilical cords for TfR analysis and microscopy. Representative histograms of fluorescence versus light scatter from these three groups were generated.
  • Y chromosomal probes were used because it is the Y chromosome that is unquestionably fetal in origin.
  • the assessments were designed to study whether the presence of Y chromosomal DNA in maternal blood as detected on autoradiographs performed antenatally correlated with the subsequent birth of a male infant.
  • HLe-1 negative cells from cord blood and pregnant women were sorted into test tubes.
  • Conventional methods of DNA isolation as well as modification of cruder methods (Lau, Y-F, et al. Lancet, 1:14-16 (1984); McCabe, E. R. B., et al., Hum Genet., 75:213-216 (1987) were attempted without success in detecting Y chromosome derived bands on Southern Blots. All were limited by the small numbers of cells present.
  • PCR which has a capacity for making 10 6 copies of rare target gene sequences, was used to amplify gene sequences in sorted fetal cells.
  • Optimum conditions for PCR given the minute amounts of DNA expected after a fetal cell sort (approximately 1 pg to 100 ng), were determined.
  • Experimental conditions were modified as new information became available. For example, Taq polymerase was used instead of Klenow fragment of E. coli DNA polymerase (Kogan, S. C. et al., New England J. Med. 317:990 (1987)) because of its increased specificity in DNA replication.
  • DNA from male and female individuals was prepared in tenfold dilutions (1 pg to 1 mcg) and amplified using the standard reagents in the GeneAmpkit (Perkin-Elmer Cetus cat #N801-0055) on a Perkin-Elmer DNA Thermal Cycler.
  • Primers 411-01 and 411-03 were designed to amplify a 222 base pair (bp) sequence within probe Y411. The number of amplification cycles varied between 18 and 30.
  • Amplified DNA samples were electrophoresed on agarose gels, transferred to nylon filters, and hybridized to 32 P-labeled Y411 probe.
  • candidate fetal cells from the peripheral blood of 19 women at 121 ⁇ 2 to 17 weeks gestation were sorted. Monoclonal antibody against TfR was used to identify the presumed NRBC. The DNA in the sorted cells was amplified for the 222 bp sequence in probe Y411 as proof that the cells were derived from the fetus in male pregnancies.
  • the fetuses were female. Therefore, detection of the Y chromosomal sequence was successful in 6/8 of 75% of the male-bearing pregnancies. In the two pregnancies where male DNA was not detected, there may have been fetomaternal blood group incompatibility. Alternatively, there may not have been fetomaternal hemorrhage or the number of NRBCs present may have been below the limit of sensitivity for detection of DNA.
  • the conditions used made it possible to detect a minimum of 100 pg of fetal DNA, or the equivalent of 15 fetal cells.
  • the limit of sensitivity can be improved by extending the number of cycles used in PCR. This work demonstrated that for the first time, fetal DNA was detected in cells isolated from maternal blood.
  • PCR is being carried out using primers derived from a single copy of sequence specific for the long arm of the Y chromosome, PY49a (Guerin, P., et al., Nucleic Acids Res., 16:7759 (1988)).
  • PY49a a single copy of sequence specific for the long arm of the Y chromosome
  • Y chromosomal DNA is visible on ethidium-bromide stained agarose gels. This extraordinary degree of sensitivity will now be applied to DNA from sorted fetal cells.
  • Maternal venous blood samples are collected from pregnant women, generally prior to any invasive procedures. In general, a single 20 ml. venous blood sample will be obtained. In a subgroup of patients, permission will be sought to draw blood samples every 4 weeks to follow changes in numbers of fetal cells present. Blood is collected in EDTA, diluted 1:1 with Hanks Balanced Salt Solution (HBSS), layered over a Ficoll-Hypaque column (Pharmacia) and spun at 1400 rpm for 40 minutes at room temperature. The mononuclear cell layer will be isolated, washed twice with HBSS and stained with fluorescent monoclonal antibodies.
  • HBSS Hanks Balanced Salt Solution
  • this can be a combination of fluorescein isothiocyanate-conjugated antitransferrin receptor (TfR) and phycoerythrin-conjugated anti-monocyte antibodies (M3, Becton-Dickinson catalog 17497) and anti-lymphocyte antibodies (L4, Becton Dickinson catalog #7347).
  • TfR fluorescein isothiocyanate-conjugated antitransferrin receptor
  • M3 phycoerythrin-conjugated anti-monocyte antibodies
  • L4 Becton Dickinson catalog #7347 anti-lymphocyte antibodies
  • Data will be acquired on the relative size and fluorescence (in two colors) of the analyzed cells.
  • Cells that are fluorescent in the green wavelength (TfR positive) and not fluorescent in the red wavelength (L4 and M3 negative) will contain the presumed fetal NRBCs. The percentage of these cells in the mononuclear cell layer are recorded and analyzed as a function of gestational age. These cells are sorted for microscopy and PCR amplification.
  • cells that are not fluorescent in the green wavelength (TfR negative) but are fluorescent in the red wavelength (L4 and/or M3 positive) are sorted as a presumed maternal leucocyte population and source of maternal DNA polymorphisms.
  • An additional benefit of studying nucleated fetal cells in maternal blood is that the amount of fetal DNA present can be extrapolated to determine the extent of fetomaternal hemorrhage in normal and unusual pregnancies. In the pregnancies studied, an average amount of 1 ng of fetal DNA (corresponding to 150 NRBCs) was present. Using published values of the number of NRBCs per liter of fetal blood at 16 weeks, (3.6 ⁇ 10 9 )(Millar, D. S. et al., Prenat. Diagnosis, 5:367-373 (1985); (Forestier, F., et al., Pediatr.
  • FITC fluorescein
  • PE phycoerythrin
  • FIG. 4 represents a summation of samples obtained from twelve women bearing male fetuses. These samples were taken at different times in pregnancy, and one woman was sampled twice. The data indicates that there is a relationship betwen gestational age and the detection of male DNA. This implies a potential biologic “window” for the transfer of fetal nucleated erythrocytes into the maternal circulation.
  • the mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation and incubated with the monoclonal antibodies fluorescein (FITC)-conjugated anti-TfR, phycoerythrin (PE)-conjugated anti-Leu 4 and PE-conjugated anti-Leu M3 (Becton-Dickinson). Dual color analysis and flow sorting were performed on a fluorescence-activated cell sorter.
  • FITC fluorescein
  • PE phycoerythrin
  • PE-conjugated anti-Leu M3 Becton-Dickinson
  • Umbilical cord blood samples (10 ml) were collected in EDTA from normal newborns. The mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation. Cell counts were performed with a hemocytometer. Separate aliquots of cells were made containing: 1) female cells alone; 2) female cells plus 10 2 added male cord blood cells; 3) 3 female cells plus 10 3 added male cord blood cells; 4) female cells plus 10 4 added male cord blood cells; 5) female cells plus 10 5 added male cord blood cells; 6) female cells plus 10 6 added male cord blood cells; 7) male cord blood cells alone.
  • the separate aliquots were then incubated with the individual monoclonal antibodies being tested. Analysis and sorting were performed using a flow cytometer. For each aliquot, a bivariate histogram was obtained, and gating parameters were established for antibody positive and antibody negative cells. The sorted cells were collected into sterile micro test tubes and frozen at ⁇ 20° C. PCR amplification was performed with primers that detect a 397 bp sequence unique to the Y chromosome. The presence of a band at 397 bp in autoradiographs was used to confirm the presence of male umbilical cord blood cells in sorted samples.
  • FIG. 5 shows the histograms obtained when FITC-anti transferrin receptor is used.
  • 0.1% of the mononuclear cells react with the antibody.
  • male cord blood 24.9% of the mononuclear cells react with the antibody.
  • more and more umbilical cord cells to the non-pregnant female cells, and increased percentage of cells that react with the antibody is seen.
  • FIG. 6 shows that male DNA is detected in the TfR + cells when 10 2 -10 6 male cells are added.
  • Male DNA is detected in the TfR ⁇ cells when 10 5 -10 6 male cells are added. This results from the presence of male white blood cells in the TfR ⁇ population.
  • FIG. 7 shows the histograms obtained when anti HPCA-1 antibody is used.
  • the non-pregnant female 0.9% of the mononuclear cells react with antibody.
  • umbilical cord blood a well-defined population of cells is seen, but the percentage is only 1.1%.
  • the addition of umbilical cord blood cells to the nonpregnant female cells is not seen on the histograms as clearly as with the transferrin receptor antibody.
  • An increased number of HPCA + cells were collected as the amounts of added cord blood cells increased.
  • a DNA probe set was constructed of chromosome specific probes that provided both good signal to noise ratios and good spatial resolution of the fluorescent signals. Accordingly, specific probes were developed for five chromosomes frequently seen as liveborn aneuploidies; chromosomes 13, 18, 21, X and Y. A probe for chromosome 1 was used as a control. In constructing the probes, the general strategy was to identify a starting clone that mapped to the desired chromosomal region by multiple genetic and physical methods, and then to use that clone to identify a matching cosmid “contig” which was then used as a hybridization probe.
  • Hybridization of the high copy number repeat sequences was suppressed by inclusion of total genomic human DNA, and the chromosomal specificity verified by hybridization to metaphase spreads.
  • the probes gave sharp, punctate fluorescent signals in interphase cells that were easily discriminated and enumerated.
  • the Y probe used in this study was pDP97, a repetitive clone (a 5.3 kb EcoRI Y fragment from cosmid Y97 subcloned into EcoRI site of pUC-13). All probes were labeled with biotin, hybridized under suppression conditions, and specific hybridization detected by conjugated streptoavidin-FITC, which showed as a single “dot” in the FITC image. As illustrated in FIG.
  • the Y chromosome was detected by in situ hybridization of a pDP97 probe for the Y chromosome in a fetal nucleated red blood cell.
  • prenatal diagnosis for chromosomal abnormalities could be performed on fetal cells isolated from maternal blood.
  • Venous blood samples (20 ml) were collected in EDTA or citrate dextrose from healthy women with uncomplicated pregnancies, prior to invasive diagnostic procedures, at different points in gestation.
  • the mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation and incubated with monoclonal antibodies directed against antigens expressed on the cell surface of hematopoietic progenitor cell. These antibodies are described in Example 2.
  • the antibodies were either directly or indirectly conjugated to a fluorescent dye. Analysis and flow sorting of fluorescent cells were performed on a fluorescence-activated cell sorter. Fluroescent cells are cells that have bound antibody recognizing primitive cell surface antigens; thus, they are hematopoietic precursor cells.
  • PCR polymerase chain reaction
  • the primers selected amplified material from the Y chromosome as a means of detecting male fetal cells. These primers defined a 397 base pair sequence.
  • the patient samples were analyzed with conventional Southern blots using a 32 P labeled probe. Ethidium bromide stained agarose gels and autoradiographs were examined for the presence of the amplified 397 bp band, which was considered significant only if reagent controls did not reveal false positive amplification.
  • CD34 human progenitor cell antigen
  • antibodies were used against the oncofetal antigen expressed in many leukemias (CALLA) to detect fetal lymphoblasts in the maternal circulation. This antibody is designated as CD10. Seventeen women have been sorted with antibody to CD10. In 8/17, evidence of male fetal DNA has been detected in CD10+ cells.
  • CALLA oncofetal antigen expressed in many leukemias
  • Human fetal umbilical cord blood is being used as a source of mononuclear cells for study of fetal cell populations, in order to determine additional antibodies to detect fetal hematopoietic cells in material circulation. Pure fetal blood samples were tested from as early as 19 weeks gestation.
  • the mononuclear cell layer is isolated as described in example 10. Mononuclear cells are incubated with mouse monoclonal antibodies to human stem cell antigens (CD34, CD10, CD38, which recognizes myeloblasts, CD33, HLA-DR, CD36, glycophorin A, CD71, 8G12, THB-7 and others). Many of these antibodies are available directly conjugated to a fluorescent dye. If the antibody is not fluorescent, a sandwich technique is used to attach fluorescein-conjugated goat anti mouse antibody to the primary antibody.
  • human stem cell antigens CD34, CD10, CD38, which recognizes myeloblasts, CD33, HLA-DR, CD36, glycophorin A, CD71, 8G12, THB-7 and others.
  • Many of these antibodies are available directly conjugated to a fluorescent dye. If the antibody is not fluorescent, a sandwich technique is used to attach fluorescein-conjugated goat anti mouse antibody to the primary antibody.
  • Venous blood samples (20 ml) were collected in EDTA or citrate dextrose from healthy women with uncomplicated pregnancies, prior to invasive diagnostic procedures, at different points in gestation.
  • the mononuclear cell layer was isolated as described in Example 10.
  • mononuclear cells cobld be obtained by (nonnucleated) red cell lysis buffers.
  • the specific monoclonal antibodies chosen to label the fetal cells of interest are CD36 and glycophorin A, used singly or in combination. These antibodies are either directly or indirectly conjugated to a fluorescent dye.
  • CD36 recognizes a cell surface antigen present on nucleated erythrocytes and monocytes, whereas glycophorin A recognizes an antigen present on erythrocytes. Fluorescent cells that have bound either or both antibodies were flow sorted; such cells were frozen and subsequently amplified for Y chromosomal sequences by the polymerase chain reaction as described in Example 10.
  • a peripheral blood sample (20 ml.) was obtained from a pregnant woman at nineteen weeks of gestation.
  • a previous ultrasound examination performed at 17 weeks gestation revealed fetal malformations consistent with a diagnosis of Down Syndrome.
  • An amniocentesis was performed for fetal chromosome analysis and results of the karotype were 47, XY, +21.
  • the woman's venous blood was collected in ethylenediamine tetraacetic acid (EDTA), diluted 1:3 with Hanks' balanced salt solution, layered over a Ficoll/Hypaque column (Pharmacia) and spun at 2000 rpm for twenty minutes at room temperature.
  • the mononuclear cell layer was isolated, washed with phosphate buffered saline (PBS) and centrifuged at 1400 rpm for ten minutes at 4° C.
  • the cell pellet was incubated with a 1:10 dilution of fluorescein-conjugated anti-TfR (anti CD 71) Becton-Dickinson Catalog No. 7513) in PBS on ice for thirty minutes.
  • the cells were washed once in PBS prior to flow sorting.
  • the probe sets used for hybridization to the Y chromosome and to chromosome 21 have been described previously (Klinger et al., cited supra, (1992)).
  • the Y chromosome probe was labeled with biotin-dUTP (Sigma) and the chromosome 21 probe was labeled with digoxigenin-dUTP (Boehringer Mannheim).
  • the probes were hybridized simultaneously under suppression conditions (Cremer et al., Hum Genet 80:235-246 (1988); Lichter et al., Hum Genet 80:224-234 (1988)).
  • the Y chromosome probe was detected with avidin conjugated to Texas Red (Vector Laboratories) and the chromosome 21 probe was detected with anti-digoxigenin conjugated to fluorescein isothiocyanate (FITC) (Boehringer Mannheim).
  • the slides were mounted in 2.33% DABCO (1,4-diazobicyclo[2.2.2]octane) (Sigma) in 100 mM Tris-HCl, pH 8.0, 90% (v/v) glycerol with 0.5 ug/ml 4,6-diamidino-2-phenyl-indole (DAPI) as a counterstain (Sigma).
  • TfR ⁇ cells In situ hybridization studies performed on the TfR ⁇ cells revealed the presence of numerous nuclei. Control slides prepared from male lymphocytes gave bright signals with both the 21 and Y probes. The nuclei from TfR ⁇ cells that hybridized to the probes were exclusively maternal, with two signals for chromosome 21 and no signal with the Y. The majority of the sorted cells in the TfR + fraction did not hybridize, due to the fact that most of them were reticulocytes, which are anucleate. Most of the nuclei present were in a few giant clumps that had retained large amounts of cytoplasm. Of the few TfR + cells that did hybridize, FITC and Texas Red signals were generally weak.

Abstract

A method of detecting the presence or absence of the fetal DNA sequence of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman is described. The method involves obtaining a sample peripheral blood from a pregnant woman, treating the sample of peripheral blood such that the fetal DNA present in the fetal nucleated cells is made available for detection and detecting the presence or absence of the fetal DNA sequence of interest in the available fetal DNA. The proportion of fetal nucleated cells present in the sample of peripheral blood can be increased forming a sample enriched in fetal nucleated cells prior to the detection step. The fetal DNA sequence of interest can be detected by treating the peripheral blood sample such that fetal DNA present in the sample is made available for hybridization with a DNA probe and subsequently contacting the available fetal DNA with a DNA probe hybridizable to fetal DNA of interest under hybridization conditions. The presence or absence of hybridization between the DNA probe and the fetal DNA of interest is detected as an indication of the presence or absence of the fetal DNA of interest.

Description

    RELATED APPLICATIONS
  • This application is a continuation-in-part application of U.S. Ser. No. 07/772,689, filed on Oct. 7, 1991, which is a continuation-in-part application of U.S. Ser. No. 07/706,393, filed on May 28, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/436,057, filed on Nov. 13, 1989, now abandoned, all being entitled “Non-Invasive Method for Isolation and Detection of Fetal DNA” by Diana W. Bianchi. The contents of all of the forementioned applications are hereby expressly incorporated by reference.[0001]
    • FUNDING
  • [0002] Work described herein was supported by the National Institute of Health and Children's Hospital Medical Center.
    • BACKGROUND
  • A variety of fetal cell types—platelets, trophoblasts, erythrocytes and leucocytes—cross the placenta and circulate transiently within maternal blood (Schroder, J., [0003] J. Med. Genet. 12:230-242 (1975); Douglas G. W. et al., Am. J. Obstet. Gynec., 78:960-973 (1959)). There have been numerous reports of efforts to separate fetal cells from maternal cells present in maternal blood, but none has been successful in isolating cells subsequently shown to contain fetal DNA. Distinguishing fetal cells from maternal cells has not been successful for several reasons, including the small number of fetal cells in a maternal blood sample and the fact that morphological differences are slight (e.g., trophoblasts are the only fetal cells which can be distinguished from maternal cells by morphology alone).
  • Others report screening the peripheral blood of pregnant women for cells of fetal origin. Fetal identification relied on the presence of a single cytogenetic marker, the Y chromosome. Lymphocytes with a putative “XY” karyotype were found in the maternal circulation as early as 14 weeks gestation (Walknowska, J., et al., [0004] The Lancet, 1119-1122 (1979)).
  • The availability of flow cytometry has led many to suggest that fetal cells could be obtained through the use of a flow cytometer and that such cells could be exploited for prenatal genetic diagnosis. However, although cells sorted in this manner have been said to be of fetal origin, based on analysis of cell surface antigens, morphology, or cytogenetic criteria, there has not been confirmation that the cells contain fetal DNA. A method by which fetal DNA could be obtained from maternal blood during pregnancy would be valuable, particularly if it made it possible to carry out prenatal diagnosis by a noninvasive technique. [0005]
    • DISCLOSURE OF THE INVENTION
  • The present invention is based, at least in part, on the discovery that fetal nucleated cells are present in the peripheral blood of a pregnant woman at a level which allows them to be useful in prenatal diagnostic methods. The method of the present invention is non-invasive because a peripheral blood sample from pregnant women, not fetal blood, is used as the source of the fetal DNA. The fetal DNA is derived from fetal nucleated cells present in the peripheral blood of a pregnant woman. The method of the present invention can be used to assess fetal characteristics (e.g. fetal sex and chromosomal abnormalities) or can be used to diagnose whether a fetus has a prenatal disease at an early stage of the gestational period. The non-invasive method of the present invention does not expose the fetus or mother to risks, e.g. infection, fetal injury, and miscarriage, associated with invasive methods such as amniocentesis. [0006]
  • The present invention pertains to a method of detecting the presence or absence of a fetal DNA sequence of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman. The method involves obtaining a sample peripheral blood from a pregnant woman, treating the sample of peripheral blood such that the fetal DNA present in the fetal nucleated cells is made available for detection and detecting the presence or absence of the fetal DNA sequence of interest in the available fetal DNA. The proportion of fetal nucleated cells present in the sample of peripheral blood can be increased forming a sample enriched in fetal nucleated cells prior to the detection step. The fetal DNA sequence of interest can be detected by treating the peripheral blood sample such that fetal DNA present in the sample is made available for hybridization with a DNA probe and subsequently contacting the available fetal DNA with a DNA probe hybridizable to fetal DNA of interest under hybridization conditions. The presence or absence of hybridization between the DNA probe and the fetal DNA of interest is detected as an indication of the presence or absence of the fetal DNA of interest. [0007]
  • The method of the present invention can be used to determine the sex of a fetus by contacting the peripheral blood sample from a woman pregnant with a fetus with a DNA probe hybridizable to fetal Y chromosomal DNA. The presence of hybridization between the DNA probe and the fetal Y chromosomal DNA can be detected as an indication of a male fetus or the absence of hybridization can be detected as an indication of a female fetus. [0008]
  • The method of the present invention also may be used for diagnosing a disease in a fetus. A sample of peripheral blood obtained from a woman pregnant with a fetus is contacted with DNA probe hybridizable to fetal DNA of interest associated with a disease under hybridization conditions. The presence or absence of hybridization between the DNA probe and the fetal DNA of interest is detected as an indication of whether the fetus has the disease. [0009]
  • The method of the present invention further can be used to detect a chromosomal abnormality in a fetus such as a chromosomal aneuploidy, e.g., [0010] trisomy 13, trisomy 18, or trisomy 21. A sample of peripheral blood from the woman pregnant with a fetus is obtained. The fetal nucleated cells are separated from the peripheral blood sample onto a solid support forming immobilized fetal nucleated material, e.g. metaphase or interphase nuclei. The immobilized fetal nucleated material is contacted with a DNA probe hybridizable to chromosomal fetal DNA of interest under hybridization conditions. The presence or absence of hybridization between the DNA probe and the chromosomal fetal DNA of interest is detected as an indication of the presence or absence of a chromosomal abnormality.
  • The method of the present invention further can be used to determine whether a pregnancy is at risk. Fetal blood hemhorrages into the maternal blood system typically occur when a pregnancy is at risk increasing the number of fetal cells present in the maternal blood. A peripheral blood sample can be obtained from a pregnant woman at a selected gestational age and the number of fetal cells present in the sample can be detected. This detected number of fetal cells can be compared to a known standard representative of the number of cells present at the selected gestational age during a normal pregnancy. The standard can be established by taking peripheral blood samples from a group of women at the selected gestational age believed to be having normal pregnancies. [0011]
  • Other aspects of this invention relate to methods of enriching the peripheral maternal blood sample and kits containing reagents used to conduct the described methods. These aspects are described in more detail below.[0012]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic representation of the method of the present invention by which fetal nucleated cells are isolated from maternal cells and DNA within the fetal cells is assessed for the occurrence of a particular fetal DNA sequence. [0013]
  • FIG. 2 is an autoradiograph of diluted male DNA amplified for 222 bp sequence. Lane 1: reagent control; lane 2: φ174 molecular weight standard; lane 3: 100 ng; lane 4: 10 ng; lane 5: 1 ng; lane 6: 200 pcg; lane 7: 10pcg; lane 8: 1 pcg. [0014]
  • FIG. 3 is a composite autoradiograph of amplified patient DNA. Lane 1: 10 ng normal male; lane 2: 10 ng normal female; lane 3: reagent control; lane 4: φX174; lane 5: sorted cells from patient 1 (male fetus); lane 6: sorted cells from patient 2 (male fetus); lane 7: sorted cells from patient 3 (female fetus); lane 8: sorted cells from patient 6 (female fetus); lane 9: sorted cells from patient 7 (male fetus); lane 10: sorted cells from patient 8 (male fetus); lane 11: sorted cells from patient 9 (female fetus); lane 12: cord blood from female infant whose cells were prenatally sorted in [0015] lane 8.
  • FIG. 4 is a diagram demonstrating the detection of Y chromosomal DNA sequences at various points of gestation in women bearing male pregnancies. [0016]
  • FIGS. 5A, 5B, [0017] 5C, 5D, 5E and 5F are a series of histograms obtained when FITC-anti transferrin receptor was used to determine the presence of mononuclear cells in samples from non-pregnant females to which male cells have been added.
  • FIG. 6 is a composite autoradiograph of amplified male DNA detected in TfR cells when 10[0018] 2-106 male cells are added to samples from non-pregnant females and in TfR− cells when 105-106 male cells are added to samples, from non-pregnant females.
  • FIGS. 7A, 7B, [0019] 7C, 7D, 7E, 7F, 7G and 7H are a series of histograms obtained when anti HPCA-1 antibody was used to determine the presence of mononuclear cells in samples from nonpregnant females to which male cells have been added.
  • FIG. 8 is a photograph illustrating a fluorescent cell due to the positive results of in situ hybridization of the pDP97 probe for the Y chromosome to a fetal nucleated red blood cell. [0020]
  • FIG. 9 is a two-dimensional bivariate histogram depicting forward angle light scatter on the X axis (an indication of cell volume) and fluorescence intensity on the Y axis (a measure of cells binding the TfR antibody. The TfR[0021] + cells respresenting 1.3% of the maternal mononuclear cells are encased in a box.
  • FIG. 10 is a photomicrograph of a flow-sorted interphase fetal nucleus isolated from maternal blood. The single black dot represents hybridization to the Y chromosome and the three white dots represent hybridization to the chromosome 21s. The karotype of this nucleus is 47, XY, +21.[0022]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to an in vitro method of separating or isolating fetal nucleated cells present in the blood of a pregnant woman (a maternal blood sample) from the pregnant woman's cells and of separating or isolating fetal DNA from maternal DNA. It further related to an in vitro method of prenatal detection and/or quantitation of selected fetal DNA in fetal DNA isolated from the maternal blood sample. The method provides a noninvasive approach to detect and/or quantitate fetal DNA, such as that associated with a disease or a condition whose assessment during gestation is desired. It also provides a noninvasive means by which the sex of a fetus can be determined. [0023]
  • In the present method, fetal nucleated cells are isolated from a maternal blood sample by means of a detectable material which binds to the fetal nucleated cells but not to maternal cells and is then separated from the maternal sample, resulting in separation of the fetal nucleated cells from the sample. The fetal nucleated cells can be any undifferentiated hematopoietic cell and, particularly, fetal nucleated erythrocytes. In one embodiment of the present method of isolation, at least one detectably labelled monoclonal antibody specific for an antigen present on fetal nucleated cells, but not for an antigen present on maternal cells, is combined with a maternal blood sample and, once bound to fetal nucleated cells, is separated from the maternal sample. Alternatively, at least one detectably labelled monoclonal antibody specific for an antigen present on maternal cells, but not for an antigen present on fetal nucleated cells is used. In a further embodiment, the two types of monoclonal antibodies are used. [0024]
  • In the case in which the detectable label is a fluorescent molecule, separation is carried out by means of flow cytometry, in which fluorescently-labelled molecules are separated from unlabelled molecules. This results in separation of fetal nucleated cells, such as fetal nucleated erythrocytes, from maternal cells and, thus, of fetal DNA from maternal DNA. That this separation has occurred can be verified using known techniques, such as microscopy or detection of fetal hemoglobin. [0025]
  • In one embodiment of the method of the present invention by which the occurrence of a selected DNA sequence or sequences (gene(s) or gene portion(s)) in fetal DNA is determined (detected and/or quantitated), the isolated fetal nucleated cells, such as fetal nucleated erythrocytes, are treated to render DNA present in them available for amplification. Amplification of DNA from fetal nucleated cells (fetal DNA) is carried out using a known amplification technique, such as the polymerase chain reaction (PCR). Amplified fetal nucleated cell DNA is subsequently separated on the basis of size (e.g., by gel electrophoresis) and contacted with a selected labelled probe, such as labelled DNA complementary to a selected DNA sequence (e.g., complementary to an abnormal gene or gene portion, or Y-specific DNA). Detection of the labelled probe after it has hybridized to fetal DNA results in detection of the sequence of interest in the fetal DNA. Quantitation of the hybridized labelled probe results in quantitation of the fetal DNA. [0026]
  • In a second embodiment of the present method of determining the occurrence of a selected DNA sequence (or sequences), cells isolated as described above are sorted onto a solid support, such as a slide, and screened for chromosomal abnormalities using in situ hybridization. In this embodiment, a selected nucleic acid probe, such as a labelled DNA probe for chromosomal DNA associated with a congenital abnormality, is combined with the fetal DNA, under conditions appropriate for hybridization of complementary sequences to occur. Detection and/or quantitation of the labelled probe after hybridization results in detection and/or quantitation of the fetal DNA to which the probe has hybridized. [0027]
  • The following is a description of the basis for the subject method; of the present method of isolating nucleated fetal cells present in the blood of a pregnant woman from maternal cells and, subsequently, separating fetal DNA from maternal DNA; and of the present method of prenatal determination of the occurrence (presence/absence or quantitation) of selected DNA in fetal cells. [0028]
  • Potential Sources of Fetal Genes [0029]
  • It has been determined that several types of fetal cells present in the blood of a pregnant woman are a source of fetal genes. In particular, it has been shown that fetal cells, such as nucleated erythrocytes (also referred to as fetal NRBC), and other undifferentiated hematopoietic precursor cells, such as erythroblasts, lymphoblasts and myeloblasts, can be isolated or separated from maternal blood. Fetal nucleated erythrocytes were particularly selected for sorting based on the following rationale: [0030]
  • 1. In any given fetomaternal hemorrhage, no matter how small, the ratio of fetal erythrocytes to fetal lymphocytes should remain the same as in whole fetal blood; thus, there would be 1,000 times as many red cells as white cells available for analysis. [0031]
  • 2. Normal pregnant females do not usually have circulating NRBC; therefore, an isolated NRBC would a priori have a greater chance of being fetal in origin. [0032]
  • 3. The majority of pregnancies are blood group compatible, which means that the “transfused” NRBC would probably be tolerated by the mother and remain in her circulation. [0033]
  • 4. Because they are nucleated, the NRBC contain a full complement of fetal genes. [0034]
  • It has been shown that fetal nucleated erythrocytes, as well as other types of fetal cells, can be isolated or separated from maternal blood and that DNA present in the isolated fetal cells can be used to assess fetal characteristics (e.g., sex, presence or absence of chromosomal abnormalities). [0035]
  • Advances in Molecular Biology Applied to Fetal Cell Sorting [0036]
  • Recent advances in molecular biology have had an enormous impact on the feasibility of fetal cell identification. For example, fluorescent in situ hybridization can be used for this purpose. [0037]
  • The development of the polymerase chain reaction (PCR) (Mullis, K., et al., [0038] Cold Spring Harb. Symp. Quant. Biol., 51:263-272 (1986), with its capacity for DNA analysis from a single cell (Li, H., et al., Nature, 355:414-417 (1988); Handyside, A. H., et al., Lancet 1:347-349 (1989)), has eliminated the technical problems associated with the small number of fetal cells in maternal blood. It makes DNA diagnosis from a single cell possible.
  • As described below, fetal nucleated erythroblasts have been shown to be present in blood obtained from pregnant women, thus making maternal blood a useful/reliable potential source of fetal DNA; fetal nucleated cells have been distinguished from maternal cells on the basis of surface antigenic characteristics, thus making it possible to separate the two cell types from one another; and fetal DNA present in the separated fetal nucleated cells has been analyzed and characterized. [0039]
  • Detection of Fetal Gene Sequences in Maternal Blood [0040]
  • One of the first steps in developing the present method of isolating fetal nucleated cells from the maternal blood supply was identification of monoclonal antibodies that permit identification and separation of fetal cells from maternal cells present in blood obtained from a pregnant woman. This has been done, as described in detail in the Examples. As a result, it has been determined that monoclonal antibodies which recognize maternal leucocytes and monoclonal antibodies which recognize fetal cell surface antigens are useful in separating maternal and fetal cells. The following is a brief description of monoclonal antibodies which have been shown to be useful in separating fetal nucleated cells from maternal cells present in a maternal blood sample. However, other monoclonal antibodies which distinguish between fetal and maternal cells on the basis of surface antigenic differences, can also be used in the present method. [0041]
  • The present method requires the use of at least one type of antibody which is specific for (or recognizes) a surface antigen present on fetal nucleated cells, for a surface antigen present on maternal cells, but not specific for both. That is, the present method can be carried out using one or more antibody which distinguishes fetal nucleated cells from maternal cells. The present method can be carried out using whole blood or blood treated or processed to enrich for (increase the concentration of) fetal nucleated cells. [0042]
  • Described below is the selection and successful use of monoclonal antibodies which distinguish fetal nucleated erythrocytes from maternal cells. It is to be understood, however, that in a similar manner, monoclonal antibodies which make it possible to select for another fetal nucleated cell type (or types) can be identified and used in the present method to separate fetal nucleated cell types from maternal cells (and, thus, fetal DNA sources from maternal DNA). [0043]
  • Initial efforts focused on the elimination of contaminating maternal leucocytes in the mononuclear cell layer and identification of monoclonal antibodies effective in carrying out this separation, which results in production of a maternal sample enriched in fetal nucleated cells. [0044]
  • HLe-1 (Becton-Dickinson Monoclonal center, Mountain View, Calif., catalog #7463) is a monoclonal antibody available as a direct fluorescein isothiocyanate (FITC) conjugate. It recognizes an antigen present on mature human leucocytes and on very immature erythrocyte precursors, but not on mature nucleated erythrocytes (Loken, M. E., et al., [0045] Blood, 69:255-263 (1987)). Thus, maternal leucocytes are recognized and bound, but fetal nucleated erythrocytes are not, making separation of the two possible. As described in detail in Example 1, this labelled antibody was used to eliminate maternal leucocytes in the mononuclear cell layer.
  • As is also described (Example 1), a combination of monoclonal antibodies has been used for the same purpose (i.e., elimination of maternal cells from the blood sample). As described, anti-monocyte antibody (M3) and anti-lymphocytes antibody (L4) have been used to remove maternal cells from the mononuclear cell layer resulting from density gradient centrifugation. [0046]
  • Monoclonal antibodies which recognize fetal nucleated cells but do not recognize maternal cells were also identified. As described in detail in Example 1, a monoclonal antibody which recognizes the transferrin receptor was identified. Erythroblasts have been shown to express the transferrin receptor (Loken, M. R., et al., [0047] Blood, 69:255-263 (1987)) antigen on their cell surfaces from the BFU-E stage until nuclear extrusion (Loken, M. R. et al., Blood, 69:255-263 (1987)). The transferrin receptor is also present on activated lymphocytes (Trowbridge, I. S. and M. B. Omary, Proc. Natl. Acad. Sci. USA. 78:3039-3043 (1981)), certain tumor cells (Greaves, M. et al., Int. J. Immunopharmac., 3:283-300 (1981)), and trophoblast cells (Galbraith, G. M. P. et al, Blood, 55:240-242 (1980)). Thus, such an antibody is specific for or recognizes (binds to) fetal nucleated cells, but not maternal leucocytes. As described in Example 1, commercially available fluorescein-conjugated monoclonal antibodies against the transferrin receptor (TfR) were used to separate fetal nucleated erythrocytes from maternal cells. Although the antibody is not specific for fetal nucleated erythrocytes, it facilitated their enrichment in the flow-sorted samples. Other monoclonal antibodies which are able to distinguish between fetal nucleated cells and maternal cells present in a blood sample can also be used. Such antibodies include commercially available monoclonal antibodies and those which can be produced using known techniques.
  • Separation of fetal nucleated cells from a maternal blood sample using antibodies described above can be carried out with samples of whole blood or a fraction of whole blood (i.e., one resulting from treatment or processing of whole blood to increase the proportion of fetal nucleated cells present), referred to as an enriched maternal sample. An enriched maternal sample is produced, for example, in a two-step process. The maternal sample is subjected to initial separation on the basis of size, such as by Ficoll-Hypaque density gradient centrifugation. This results in production of a supernatant layer, which contains platelets; a mononuclear cell layer; and an agglutinated pellet which contains non-nucleated erythrocytes and granulocytes. The mononuclear layer is separated from the other layers, to produce a maternal sample which is enriched in fetal nucleated cells. [0048]
  • The maternal sample, whether maternal whole blood or an enriched maternal sample, is subjected to separation, based on surface antigenic differences between fetal nucleated cells and maternal cells using antibodies described above. The maternal sample is contacted with at least one monoclonal antibody which is specific for either fetal nucleated cells or maternal cells, but not for both and, thus, makes it possible to separate the two types of cells. The maternal sample can be combined with a set of two or more monoclonal antibodies, each of which is specific for either fetal or maternal cells, but not for both. The combination of monoclonal antibodies can be designed to enhance separation of the two types of cells (e.g., the combination of anti-TfR antibody and HLe-1 antibody described previously) beyond that possible with a single monoclonal antibody. Separation of the fetal cells is carried out using known techniques, such as flow cytometry, use of immunomagnetic beads and cell panning. In general, the monoclonal antibodies have a detectable label (e.g., radioactive material, fluorophore). [0049]
  • In some cases, fetal nucleated cells persisting from a previous pregnancy may be present in the peripheral blood sample. Steps may be taken to eliminate or significantly reduce the number of such residual nucleated cells if found to be present. Alternatively, a type of fetal nucleated cell known to be associated with the present pregnancy may be selected for detection obviating any potential interference or contamination of the detection method by the residual fetal nucleated cells. For example, fetal nucleated cell type having a relatively short life span may be selected for detection ensuring the fetal nucleated cell is not from a previous pregnancy. Fetal nucleated erythrocytes typically have a life span of about three months in the maternal circulation. The above-identified steps can be conducted using monoclonal antibodies which recognize antigens on the respective cells. [0050]
  • An embodiment of the method of the present invention by which fetal cells are isolated and fetal DNA is detected is represented schematically in FIG. 1. A maternal blood sample (typically 20 ml.) is obtained, using known techniques. The sample is separated into component layers on the basis of size and the mononuclear cell layer, referred to as the maternal sample enriched in nucleated cells (or enriched maternal sample), is removed for further processing. The enriched maternal sample is contacted with at least one monoclonal antibody, as described above, and the resulting fetal nucleated cell/antibody complexes are separated using known methods (e.g., flow cytometry, immunomagnetic beads, cell panning). Fetal DNA is crudely extracted from the resulting complexes (e.g., by heat), thus rendering it available for hybridization with nucleic acid probes. Fetal DNA can be analyzed for a selected DNA sequence or DNA sequences, using known techniques. Prior to analysis, fetal DNA can be amplified, as needed, using known methods (e.g., PCR). [0051]
  • If amplification is to be carried out, the sorted samples are amplified for an appropriate number of cycles of denaturation and annealing (e.g., approximately 24-60). Control samples include a tube without added DNA to monitor for false positive amplification. With proper modification of PCR conditions, more than one separate fetal gene can be amplified simultaneously. This technique, known as “multiplex” amplification, has been used with six sets of primers in the diagnosis of DMD (Chamberlain, J. S., et al., [0052] Prenat. Diagnosis, :349-355 (1989)). When amplification is carried out, the resulting amplification product is a mixture which contains amplified fetal DNA of interest (i.e., the DNA whose occurrence is to be detected and/or quantitated) and other DNA sequences. The amplified fetal DNA of interest and other DNA sequences are separated, using known techniques. Subsequent analysis of amplified DNA can be carried out using known techniques, such as: digestion with restriction endonuclease, ultraviolet light visualization of ethidium bromide stained agarose gels, DNA sequencing, or hybridization with allele specific oligonucleotide probes (Saiki, R. K., et al, Am. J. Hum. Genet., 43 (Suppl):A35 (1988)). Such analysis will determine whether polymorphic differences exist between the amplified “maternal” and “fetal” samples. In one embodiment, the amplification mixture is separated on the basis of size and the resulting size-separated fetal DNA is contacted with an appropriate selected DNA probe or probes (DNA sufficiently complementary to the fetal DNA of interest that it hybridizes to the fetal DNA of interest under the conditions used). Generally, the DNA probes are labelled (e.g., with a radioactive material, a fluorophore or other detectable material). After the size-separated fetal DNA and the selected DNA probes have been maintained for sufficient time under appropriate conditions for hybridization of complementary DNA sequences to occur, resulting in production of fetal DNA/DNA probe complexes, detection of the complexes is carried out using known methods. For example, if the probe is labelled, fetal DNA/labelled DNA probe complex is detected and/or quantitated (e.g., by autoradiography, detection of the fluorescent label). The quantity of labelled complex (and, thus, of fetal DNA) can be determined by comparison with a standard curve (i.e., a predetermined relationship between quantity of label detected and a given reading).
  • The present method has been used to identify Y-specific DNA in nucleated erythrocytes obtained from peripheral blood of pregnant women. This is described in Example 4. Briefly, candidate fetal cells from blood samples obtained from 19 pregnant women were isolated by flow sorting. The DNA in these cells was amplified for a 222 base pair (bp) sequence present on the short arm of the Y chromosome as proof that the cells were derived from the fetus. The amplified DNA was compared with standardized DNA concentrations; 0.1 to 1 ng fetal DNA was obtained in the 20 ml maternal samples. In 7/19 cases, a 222 bp band of amplified DNA was detected, consistent with the presence of male DNA in the isolated cells; 6/7 of these were confirmed as male pregnancies by karyotyping amniocytes. In the case of the female fetus, DNA prepared from cord blood at delivery also showed the presence of the Y chromosomal sequence. In 10/12 cases where the 222 bp band was absent, the fetuses were female. Thus, the Y chromosmal sequence was successfully detected in 75% of the male-bearing pregnancies, demonstrating for the first time that it is possible to isolate fetal gene sequences from maternal blood. [0053]
  • As described in Example 6, male (Y-specific) DNA has been detected in cells sorted from pregnant women at various points in gestation. Briefly, the mononuclear cell layer was isolated from venous blood samples obtained from women between 11 and 16 weeks gestation. Separation was carried out using Ficoll/Hypaque density centrifugation, followed by incubation with monoclonal antibodies (Anti-TfR, [0054] anti-Leu 4 and anti-LeuM3) conjugated with a fluorescent marker or compound (fluorescein, phycoerythrin) and dual color analysis and flow sorting on a fluorescence-activated cell sorter. The cells that displayed green fluorescence, but not red fluorescence (TfR positive, Leu negative, Leu M3 negative), were fetal nucleated cells and were separated from the remainder of the sample. These cells were lysed, after which the DNA was amplified and probed for the presence of a 397 bp sequence of the Y chromosome.
  • The results presented in Example 6 indicate the procedure allows the detection of the 397 bp sequence present in as little as 5 pg of male DNA. In addition, they suggest that there is a relationship between gestational age and detection of male DNA, as illustrated in FIG. 4. This data suggests there may be a biologic “window” for transfer of fetal nucleated erythrocytes into maternal circulation. [0055]
  • The present method also has been used to distinguish female fetal DNA from maternal DNA. The two types of female DNA were distinguished using amplification of paternal polymorphism, as described in detail in Example 7. Briefly, venous blood samples were collected from women with uncomplicated pregnancies. Separation of fetal nucleated cells was conducted using Ficoll/Hypaque density centrifugation, followed by incubation with monoclonal antibodies (anti-TfR, [0056] anti-Leu 4 and anti-Leu M3) conjugated with a fluorescent marker (fluorescein, phycoerthyrin) and dual color analysis and flow sorting on a fluorescence-activated cell sorter. Fetal nucleated cells identified by displaying green fluorescence (TfR positive), but not red fluorescence (Leu-4, Leu-3 negative), were collected and lysed. The DNA from the cells was amplified and probed for paternal sequences of the highly polymorphic region of chromosome 17, which allows the distinction of female fetal DNA from maternal DNA.
  • The results demonstrated that DNA sequences from the father can be identified in the autosomal chromosomes of the fetus. Consequently, the method of the present invention can be used to separate female fetal nucleated cells, as well as male fetal nucleated cells, from maternal blood. Thus, the method can be used for all DNA-based diagnostic procedures currently being used in other methods, such as amniocentesis. [0057]
  • Further support for the present method's capability to identify Y-specific DNA in nucleated erythrocytes obtained from peripheral blood of pregnant women is given by reconstruction experiments. As described in Example 8, male cord blood was added to blood obtained from non-pregnant females to simulate the presence of fetal cells in maternal blood. Briefly, venous blood samples were collected from healthy, non-pregnant women and the mononuclear cell layers isolated by Ficoll/Hypaque density centrifugation. Mononuclear cells from the umbilical cords of male infants (ranging from 10[0058] 2 to 106 cells) were added to the mononuclear cell layers of the blood of non-pregnant women. The cord blood contains a large percentage of nucleated erythrocytes. The results obtained from these experiments were substantially similar to those obtained from pregnant women at various stages in gestation. Amplified sequences from the Y chromosome, consistent with the presence of male DNA, were detected when 102 male cells were added to the female cells.
  • Experiments have also indicated that fetal hematopoietic stem cells, as well as nucleated erythrocytes, may be used in the isolation and identification of Y-specific DNA. Example 10 describes the procedure in detail. Briefly, venous blood samples are collected from pregnant women. The mononuclear cell layer is isolated by Ficoll/Hypaque density centrifugation and incubated with monoclonal antibodies which are conjugated with a fluorescent marker and directed against antigens on the surface of hematopoietic progenitor cells (see Example 11 for discussion of antibodies). Fluorescent cells, separated by flow sorting, have bound antibody recognizing primitive cell surface antigens, and thus, are hematopoietic precursor cells. After the cells are lysed by boiling, they are subjected to polymerase chain reaction (PCR) amplification using primers selected to amplify a 397 base pair sequence from the Y chromosome. This method was used to study twenty-five women, eleven of whom have confirmed male pregnancies. In eight of these eleven women (77%), male DNA was detected in sorted cells which showed a positive response to a human progenitor cell antigen, thus, indicating that the cells were undifferentiated hematopoietic stem cells. This experiment confirms that fetal hematopoietic stem cells are circulating in the mother's blood. An additional experiment with an antibody used to detect fetal lymphoblasts (CD10) indicated that in eight of 17 women, male fetal DNA was detected in CD10+ cells. Other antibodies have been identified which recognize human stem cell antigens, as detailed in Example 11. The data demonstrates that the types of fetal cells present vary as the pregnancy proceeds; therefore, it may be desirable to vary the type of antibody used in cell separation, depending on the length of gestation. [0059]
  • As described in Example 12, the present method has been used to analyze venous blood from healthy pregnant women for the presence or absence of Y chromosomal DNA sequences and has been shown to be highly accurate in its ability to do so, as well as to distinguish between samples from women carrying male fetuses and women carrying female fetuses. The only possible source of Y chromosomal DNA in maternal blood is male fetal cells (male cells carrying an X and a Y chromosome and female cells carry two X chromosomes). As described, two antibodies were used, alone or in combination, for this purpose: CD36, which recognizes a cell surface antigen on nucleated erythrocytes and monocytes and glycophorin A, which recognizes an antigen present on erythrocytes. The antibodies were conjugated, directly or indirectly, to a fluorescent dye. Fluorescent cells in the venous sample which bound one or both antibodies were flow sorted and later amplified for Y chromosomal sequences using PCR. Of the 18 women studied, 11 had male fetuses and 7 had female fetuses. Y chromosomal DNA sequences were detected in cells sorted with CD36 and/or glycophorin A antibodies in 10 of the 11 (91%) women with male fetuses and in none of the 7 women bearing females. These results demonstrate that these two antibodies are particularly effective in identifying fetal nucleated cells in maternal blood. [0060]
  • The results of the work described above and in the Examples demonstrate that nucleated fetal cells have been isolated from maternal blood; genomic DNA has been extracted from the fetal cells and identified as being of fetal origin; fetal genes have been amplified using PCR; and selected DNA sequences have been identified in the fetal DNA. It demonstrates for the first time that fetal DNA has been detected in cells isolated from maternal blood. [0061]
  • Uses of the Present Method of Fetal Nucleated Cell Isolation and Fetal DNA Characterization [0062]
  • Thus, it has been demonstrated that fetal DNA can be obtained from fetal nucleated cells present in a maternal blood sample. The method of detecting and/or quantitating fetal DNA which is represented in FIG. 1 is useful as a tool for prenatal assessment (e.g., as a means for assessing chromosomal abnormalities, for determining whether DNA associated with a disease is present, or for detecting Y-specific DNA). It is particularly useful because it is noninvasive and requires only a small sample of blood. [0063]
  • Fetal DNA sequences in fetal nucleated erythrocytes, isolated as described herein or by other means by which fetal nucleated cells can be separated from a maternal blood sample, can be analyzed or assessed for the occurrence of a DNA sequence or DNA sequences (gene(s) or gene portion(s)) which are of interest for diagnostic or other purposes. The DNA sequence(s) or gene(s)/gene portion(s) present in fetal cells are referred to herein as fetal DNA of interest. For example, the selected DNA whose presence or absence is to be determined and whose quantity can also be determined is the gene for a disease, such as cystic fibrosis, where the causative gene or gene portion has been cloned and sequenced; alternatively, it is a probe for X- or Y-specific DNA. The same procedure can also be used, with appropriate modifications (e.g., an appropriate DNA probe, time, temperature), to detect other genes or gene portions. [0064]
  • As used in a diagnostic context, such as to detect the gene known to cause cystic fibrosis, the present method is carried out as follows: Initially, a maternal blood sample (typically 20 ml.) is obtained and separated into component layers based on relative weights (e.g., by Ficoll-Hypaque density gradient centrifugation) to remove non-nucleated erythrocytes and produce a mononuclear cell layer. This results in production of a maternal blood sample enriched in fetal nucleated erythrocytes. The mononuclear cell layer is stained with at least one appropriate monoclonal antibody (e.g., one which is specific for the type of fetal nucleated cell to be separated from the sample). For example, a monoclonal antibody specific for fetal nucleated cells, such as anti-TfR antibody, described above, can be used. In general, the monoclonal antibody used bears a detectable label. Alternatively, a combination of selected labelled monoclonal antibodies, such as monoclonal antibodies specific for fetal nucleated cells (e.g., anti-TfR antibody) and monoclonal antibodies specific for maternal leucocytes (Hle-1 or L4 and M3), each labelled with a different fluorescent compound, can be used to remove essentially all maternal cells. Labelled cells are subsequently separated from one another using a known method, such as flow cytometry. Binding of the monoclonal antibodies to cells for which they are specific results in production of labelled monoclonal antibody-cell complexes. For example, in the case in which anti-TfR antibodies and HLe-1 are used, fetal nucleated erythrocytes are bound by anti-TfR antibody, to produce fetal nucleated erythrocytes/anti-TfR antibody complexes, and maternal leucocytes are bound by HLe-1 antibody complexes. The fetal nucleated erythrocyte/anti-TfR antibody complexes are separated from maternal cell/HLe-1 antibody complexes, using, for example, flow cytometry. The fetal cells are lysed, to produce crudely extracted fetal DNA which is subsequently amplified, using, for example, PCR. This results in production of amplified fetal DNA, which is subsequently separated on the basis of size. Size-separated fetal DNA is contacted with labelled DNA probes (i.e., in prenatal detection of cystic fibrosis, a labelled DNA probe complementary to the gene associated with cystic fibrosis). If the fetal DNA contains DNA of interest (in this case, the gene associated with cystic fibrosis), fetal DNA of interest/labelled probe complexes are formed. [0065]
  • Fetal DNA of interest/labelled probe complexes are subsequently detected, using a known technique, such as autoradiography. Simple presence or absence of labelled fetal DNA of interest can be determined or the quantity of fetal DNA of interest can be determined. In either case, the result is assessment of fetal DNA obtained from a maternal blood sample for selected DNA. [0066]
  • The occurrence of fetal DNA associated with diseases or conditions other than cystic fibrosis can also be detected and/or quantitated by the present method. In each case, an appropriate probe is used to detect the sequence of interest. For example, sequences from probes St14 (Oberle, I., et al., [0067] New Engl. J. Med., 312:682-686 (1985)), 49a (Guerin, P., et al., Nucleic Acids Res., 16:7759 (1988)), KM-19 (Gasparini, P., et al., Prenat. Diagnosis, 9, 349-355 (1989)), or the deletion-prone exons for the Duchenne muscular dystrophy (DMD) gene (Chamberlain, J. S., et al., Nucleic Acids Res., 16:11141-11156 (1988)) are used as probes. St14 is a highly polymorphic sequence isolated from the long arm of the X chromosome that has potential usefulness in distinguishing female DNA from maternal DNA. It maps near the gene for Factor VIII:C and, thus, may also be utilized for prenatal diagnosis of Hemophilia A. Primers corresponding to sequences flanking the six most commonly deleted exons in the DMD gene, which have been successfully used to diagnose DMD by PCR, can also be used (Chamberlain, J. S. et al., Nucleic Acids Res., 16:11141-11156 (1988)). Other conditions which can be diagnosed by the present method include β-thalassemia (Cai, S-P., et.al., Blood, 73:372-374 (1989); Cai, S-P., et al., Am. J. Hum. Genet., 45:112-114 (1989); Saiki, R. K., et al., New Engl. J. Med., 319:537-541 (1988)), sickle cell anemia (Saiki, R. K., et al., New Engl. J. Med., 319:537-541 (1988)), phenylketonuria (DiLella, A. G., et al., Lancet, 1:497-499 (1988)) and Gaucher disease (Theophilus, B., et al., Am. J. Hum. Genet., 45:212-215 (1989)). An appropriate probe (or probes) is available for use in the present method for assessing each condition.
  • It is also possible to separate fetal cells from maternal cells by means other than flow cytometry, as mentioned previously, and to analyze fetal nucleated erythrocyte DNA obtained in this way. Such separation procedures may be used in conjunction with or independent of flow cytometry. This is advantageous because lack of access to a flow cytometer, as well as expense, could limit potential applications of this technique. Thus, other methods of fetal cell separation can be used. The separation method used can result in elimination of unwanted cells (“negative selection”) or isolation of rare but desirable cells (“positive selection”). [0068]
  • In one embodiment, the maternal cells are depleted prior to fetal cell sorting. The mononuclear cell layer is initially isolated from the blood of pregnant women by Ficoll-Hypaque centrifugation. The resulting cell suspension consists predominantly of maternal cells; in order to enrich the eventual proportion of fetal cells present, the maternal cells are selectively removed by incubating the cells with antibodies attached to a solid support. Such supports include magnetic beads, plastic flasks, plastic dishes and columns. The antibodies bind antigens present on the cell surface of mature leukocytes. Thus, the majority of maternal leukocytes are eliminated by virtue of being bound to the solid support. The total number of cells remaining in the cell suspension is smaller, but the proportion of fetal cells present is larger. [0069]
  • Separation by immunomagnetic beads or by cell panning can also be used. In this embodiment, the mononuclear cell layer is isolated, as described previously. This layer is then mixed with antibody-coated polymer particles containing magnetic cores (e.g., “Dynabeads”). These immunomagnetic beads are available coated with a variety of antibodies. For example, immunomagnetic beads coated with antibody to leucocyte antigens and antibody to mouse immunoglobulins, which can be subsequently conjugated to mouse monoclonal antibody against the human transferrin receptor, can be used. After mixing, the rosetted cells are isolated with a magnetic particle concentrator. In one embodiment, two sets of antibody-coated immunomagnetic beads are used in succession. First, the maternal leucocytes are depleted and then the remaining TfR positive cells are collected. Subsequent steps in the method (amplification, separation, contact with an appropriate DNA probe or probe set) are as described for cells separated by flow cytometry. [0070]
  • Mueller et al. ([0071] Lancet, 336:197-200 (1990)) have described a method of isolating placenta-derived trophoblast cells in the blood of pregnant women using magnetic beads. This method included mixing 1 ml of monoclonal antibody hybridoma culture supernatant with 2×107 magnetic beads precoated with sheep antibody to mouse IgG (Fc fragment) (Dynabeads M-450, Dynal AS, Oslo, Norway), and incubated overnight at room temperature. The coated beads were stored at 4° C. and washed three times in ice-cold RPMI 1640 medium containing lithium heparin (10 IU/ml). The blood from the pregnant women was collected into tubes containing 10 IU of lithium perm1 of whole blood, diluted 1:10 with RPMI containing lithium, and incubated with the antibody coated beads at 4° C. overnight. The desired cells were bound to the antibody on the bead; the beads collected by means of a cobalt-samarium magnet. Although in this case the antibody was directed against trophoblast antigens a similar technique can be utilized with, for example, antibody to cell surface antigens present on fetal nucleated erythrocytes and not present on maternal cells. An advantage to this particular technique is that an initial step which results in mononuclear cell isolation is not added. Additionally, the magnetic beads can be used for both positive (fetal cells)and negative (maternal cells) selection.
  • An alternative method of isolation can be a modification of the method described by R. J. Berenson et al. ([0072] J. of Immunol. Methods, 91(1986)) in which the high affinity between the protein avidin and the vitamin biotin was exploited to create an indirect immuno-adsorptive procedure. In this technique, avidin was linked to cyanogen bromide activated sepahrose 6MB beads and washed in an alternating fashion with coupling buffer (0.1 M NaHCO3 in 0.5 M NaCl at pH 8.3). and washing buffer (0.1 M sodium acetate in 0.5 M NaCl at pH 4.5) and stored at 4° C. The blood cells were incubated with 1) murine monoclonal antibody, and 2) biotinylated goat anti-mouse immunoglobulin. A 3 ml column of gel was packed in Pharmacia K 19/15 column. The treated cells were passed through the column in phosphate buffered saline containing 2% bovine serum albumin. Adherent cells were dislodged by mechanical agitation. This technique can be applied to fetal cell separation if the antibodies used recognize fetal cell surface antigens or maternal cell surface antigens, but not both. Variation in methods for conjugating antibodies to beads exist; examples include those described by Thomas and co-workers (Thomas, T. E., et al. (J. of Immuno. Methods, 120:221-131 (1989)) and by deKretser and co-workers (deKretser, T. A., et al. (Tissue Antigens, 16:317-325 (1980)). The use of an antibody-bound column does not require the preliminary isolation of the mononuclear cell fraction from whole blood.
  • Another alternative to mononuclear cell isolation is to selectively lyse maternal non-nucleated erythrocytes. A number of buffers, including 0.17M NH[0073] 4Cl, 0.01M Tris, pH 7.3, have been described in the literature and are well known in isolation of hematopoietic stem cells for bone marrow transplantation. Other buffers (“Lyse and Fix”, GenTrak) are available commercially.
  • Once the fetal cells are isolated from maternal blood, they may be cultured to increase the numbers of cells available for diagnosis, if desired. E. Fibach et al. ([0074] Blood, 73:100-103 (1989)) have described a method that supports the growth of human hematopoietic progenitor cells. This step-wise method involves 1) initial culture in the presence of conditioned medium from human bladder carcinoma cells, 2) removal of leucocytes by harvest of non-adherent cells and lysis with monoclonal antibodies and 3) reculture of cells in medium supplemented by recombinant erythropoietin.
  • Other methods of separating fetal nucleated cells from maternal cells can also be used, provided that they make it possible to differentiate between fetal cells and maternal cells, and to isolate one from the other. [0075]
  • A kit for use in carrying out the present method of isolating and detecting fetal DNA of interest, such as a chromosomal abnormality associated with a disease or other condition, in a maternal blood sample can be produced. It includes, for example, a container for holding the reagents needed; the reagents and, optionally, a solid support for use in separating fetal nucleated cell/specific antibody complexes from other sample components or for removing maternal cells complexed with a specific antibody. For example, reagents in a kit to be used in detecting fetal DNA of interest after amplification of fetal DNA by PCR can include: 1) at least one antibody specific for a surface antigen characteristic of fetal nucleated cells but not specific for a surface antigen characteristic of maternal leucocytes; selected DNA primers for use in amplifying fetal DNA by PCR; and at least one DNA probe complementary to the fetal DNA to be detected (fetal DNA of interest). The kit, as indicated, can also include a solid support to be used in separating complexes formed from other samples components. Such solid support can be, for example, a glass slide, nitrocellulose filter, or immunomagnetic beads and can have affixed thereto an antibody selective for the antibody present in the fetal nucleated cell/specific antibody complexes. [0076]
  • The present invention will now be illustrated by the following examples, which are not intended to be limiting in any way. [0077]
    • EXAMPLE 1 Antibody Selection for Isolation and Sorting of Fetal Nucleated Erythrocytes (NRBCs)
  • Removal of Maternal Leucocytes from Maternal Blood Using Human Leucocyte Antigen (HLe-1) [0078]
  • The technique of fetal NRBC isolation began with an initial Ficoll-Hypaque density gradient centrifugation to remove the tremendously high number of non-nucleated erythrocytes in maternal blood. Peripheral blood was centrifuged and separated into a supernatant layer containing platelets, a mononuclear cell layer, and an agglutinated pellet consisting of non-nucleated erythrocytes and granulocytes. The mononuclear cell layer consisted of lymphocytes, monocytes, possible trophoblasts, and, due to their increased size and density, NRBCs and some reticulocytes. While the Ficoll-Hypaque centrifugation represented an initial enrichment in the proportion of fetal NRBCs present in the maternal sample, flow cytometry and cell sorting was used to improve the purity of the isolated cell population. [0079]
  • The mononuclear cell layer from peripheral blood samples in 63 pregnant women, 15 nonpregnant adults, and 39 umbilical cords, was stained with FITC-HLe-1 for flow cytometric analysis. Umbilical cord samples were used as a substitute for whole fetal blood. Representative histograms displaying fluorescence versus low-angle light scatter (an approximation of cell size) for each of the three groups were generated. Histogram peaks were identified that corresponded to leucocytes, erythrocytes and platelets. In 9 pregnant women, 7 nonpregnant adults and 12 umbilical cord samples, fluorescent (HLe-1 positive) and non-fluorescent (HLe-1 NEGATIVE) cell populations were sorted for detailed microscopy after Wright-Giemsh staining. While the HLe-1 positive populations were always composed of leucocytes independent of the sample source, the HLe-1 negative populations differed. [0080]
  • In cord blood, the HLe-1 negative cells were nonnucleated and nucleated erythrocytes with occasional platelets. In the pregnant women, there were platelets, non-nucleated erythrocytes, and a very rare NRBC. In non-pregnant adults, only platelets and debris were seen. Thus, cord blood, with it high percentage of NRBCS, was used as a reference to establish cell sorting parameters. Microscopy confirmed the specificity of the antibody-antigen binding and that the sorted HLe-1 negative cells were relatively free from leucocyte contamination. These sorting parameters were utilized to isolate potential fetal NRBC on 40 pregnancies. [0081]
  • Enrichment of Fetal NRBC in Maternal Blood Using Transferrin Receptor Antigen (TfR) [0082]
  • The transferrin receptor (Newman, R., et al., [0083] Trends Biochem. Sci. 1:397-399 (1982)) is a surface glycoprotein important in cellular iron transport. The TfR is present on activated lymphocytes (Trowbridge, I. S., et al., Proc. Natl. Acad. Sci. USA, 7:3039-3043 (1981)), certain tumor cells (Greaves, M. et al., Int. J. Immunopharmac., 3:283-300 (1981)), and trophoblast cells (Galbraith, G. M. P., et al., Blood, 55:240-242 (1980)). Erythroblasts express the TfR on their cell surfaces from the BFU-E stage until nuclear extrusion (Loken, M. R., et al., Blood, 69:255-263 (1987)). Thus, TfR is an excellent “candidate antigen” for enrichment of fetal NRBCs found in maternal blood. Monoclonal antibody against TfR is available as both a fluorescein conjugate (Becton-Dickinson catalog #7513) and a phycoerythrin (PR) conjugate (gift of Dr. Michael Loken, Becton-Dickinson). The mononuclear cell layer was isolated from peripheral blood samples in 6 pregnant women, 4 non-pregnant adults, and 3 newborn umbilical cords for TfR analysis and microscopy. Representative histograms of fluorescence versus light scatter from these three groups were generated.
  • Whereas umbilical cord samples had a large population of fluorescent TfR positive cells) that were heterogenous in size, non-pregnant adults and pregnant adults had smaller percentages of fluorescent cells that clustered in discrete groups. In addition, there were slight differences in the percentages of TfR positive cells in the pregnant (mean=0.83) versus non-pregnant (mean=0.32) samples studies. [0084]
  • Microscope studies of the TfR positive cells were performed using Wright-Giemsa stain for morphology and Kleihauer-Betke technique for the detection of fetal hemoglobin (Kleihauer, E., et al., [0085] Klin Wochenschr., 3:637-638 (1957)). In the umbilical cord samples, large numbers of nucleated and non-nucleated erythrocytes containing fetal hemoglobin and occasional leucocytes were identified visually. In the pregnant women, the predominant cell types were nucleated and non-nucleated erythrocytes containing fetal hemoglobin, although leucocytes were infrequently observed. In contrast, the samples from the non-pregnant controls consisted almost exclusively of lymphocytes and monocytes. Because trophoblast cells express TfR, it was postulated that they might be present in the sorted population from the pregnant women; none was detected.
  • Dual Antibody Analysis [0086]
  • Because both antibodies enriched the proportion of NRBCs present, but did not completely exclude other cell types in the sorted samples, combinations of antibodies were used to isolate pure populations of fetal NRBCs. Preliminary dual antibody studies were performed using PE-conjugated TfR and FITC-conjugated HLe-1. NRBCs are TfR positive and HLe-1 negative, whereas maternal leucocytes are HLe-1 positive. These experiments worked well and resulted in separation of maternal leucocytes. [0087]
  • Thus, the work described above defined flow cytometric parameters for enrichment and sorting of NRBCs in peripheral blood from pregnant women. In addition, microscopic studies revealed that morphologic differences occur in mononuclear cell populations derived from venous blood samples in pregnant versus non-pregnant adults. [0088]
    • EXAMPLE 2 DNA Hybridization Studies in HLe-1 Negative Cells Sorted from Maternal Blood
  • To confirm fetal origin of the cells sorted as described in Example 1, Y chromosomal probes were used because it is the Y chromosome that is unquestionably fetal in origin. The assessments were designed to study whether the presence of Y chromosomal DNA in maternal blood as detected on autoradiographs performed antenatally correlated with the subsequent birth of a male infant. [0089]
  • DNA Isolation [0090]
  • HLe-1 negative cells from cord blood and pregnant women were sorted into test tubes. Conventional methods of DNA isolation as well as modification of cruder methods (Lau, Y-F, et al. [0091] Lancet, 1:14-16 (1984); McCabe, E. R. B., et al., Hum Genet., 75:213-216 (1987) were attempted without success in detecting Y chromosome derived bands on Southern Blots. All were limited by the small numbers of cells present.
    • EXAMPLE 3 Direct Hybridization to Cells Deposited on Filters
  • In order to circumvent technical problems associated wtih DNA isolation, a method of direct DNA hybridization to cells flow sorted onto nitrocellulose filters was developed (Bianchi, D. W., et al., [0092] Cytometry, 8:197-202 (1987)). In control experiments, the sex of a newborn was determined from as few as 50 sorted cord blood leucocytes or 5,000 HLe-1 negative cells (a mixture of nucleated and non-nucleated cells).
  • The methodology was then applied to detection of Y chromosomal sequences in HLe-1 negative cells sorted from peripheral blood samples in 40 women between 8½% and 38 weeks gestation. Results were the following: [0093]
    Delivered Delivered Lost To
    Dot Blot Hybridization Male Female Follow-
    with Y Chromosomal Probe Infant Infant up
    + 3 2 0
    − 21 12 2
  • It was concluded that hybridization with this probe was not predictive of male pregnancy. The possibility exists that there was fetal DNA present on the filters where DNA hybridization occurred, but that this DNA bound to the Y probe nonspecifically. Thus, the filters interpreted as “positive” for male DNA might actually have been “positive” for fetomaternal hemorrhage. [0094]
    • EXAMPLE 4 Use of the Polymerase Chain Reaction (PCR) to Amplify Gene Sequences in Sorted Fetal Cells
  • PCR, which has a capacity for making 10[0095] 6 copies of rare target gene sequences, was used to amplify gene sequences in sorted fetal cells. Optimum conditions for PCR, given the minute amounts of DNA expected after a fetal cell sort (approximately 1 pg to 100 ng), were determined. Experimental conditions were modified as new information became available. For example, Taq polymerase was used instead of Klenow fragment of E. coli DNA polymerase (Kogan, S. C. et al., New England J. Med. 317:990 (1987)) because of its increased specificity in DNA replication.
  • Initially, studies were performed on repeated sequences from the long arm of the Y chromosome, probe Y431-Hinfa (given by Dr. Kirby Smith, Johns Hopkins University, Baltimore, Md.) and the short arm of the Y chromosome, probe Y411 (Given by Dr. Ulrich Muller, Children's Hospital, Boston, Mass.). Repeated sequences were selected because they would create a stronger amplification signal from a rare male fetal cell. Y411 is identical to Y156 (Muller, U., et al., [0096] Nucleic Acids Res., 14:1325-1329 (1986)), is repeated 10-60 fold, and is absolutely Y specific on Southern blots. Sequence Y431 has autosomal homology in females that limited its usefulness in sex determination.
  • PCR Standardization [0097]
  • To define the minimum amount of DNA detectable in maternal blood, a series of standardization experiments were done. DNA from male and female individuals was prepared in tenfold dilutions (1 pg to 1 mcg) and amplified using the standard reagents in the GeneAmpkit (Perkin-Elmer Cetus cat #N801-0055) on a Perkin-Elmer DNA Thermal Cycler. Primers 411-01 and 411-03 were designed to amplify a 222 base pair (bp) sequence within probe Y411. The number of amplification cycles varied between 18 and 30. Amplified DNA samples were electrophoresed on agarose gels, transferred to nylon filters, and hybridized to [0098] 32P-labeled Y411 probe. While it appeared possible to detect Y specific bands on autoradiographs in lanes containing as little as 10 pg of male DNA, results were often muddled by the presence of amplified DNA in female lanes or control lanes containing no added DNA. The phenomenon of “false positive amplification” has now received universal recognition (Lo, Y-M.D., et al., Lancet, 2:697 (1988); Kwok, S., et al, Nature, 339:237-238 (1989)).
  • Elimination of “False Positive” Amplification [0099]
  • Due to the limited amount of starting material in a fetal cell sort, every effort was made to eliminate background amplification in order to determine which fetuses truly possess Y chromosomal DNA. Thus, measures were taken to prevent aerosol contamination of male DNA. All PCRs were performed under sterile conditions, wearing gloves, and using positive displacement pipettes. All reagents were prepared in a sterile manner and incubated overnight prior to PCR with a restriction endonuclease having a digestion site within the target sequence. These precautions resulted in a significant decrease and virtual absence of false positive amplification, as monitored by running control reactions with all reagents but no DNA. [0100]
  • Successful Isolation and Amplification of Fetal Gene Sequences from NRBCs in Maternal Blood [0101]
  • After eliminating sources of DNA contamination and determining that as little as 10 pg of male DNA (1 [0102] cell 7 pg of DNA) could be detected after PCR amplification, candidate fetal cells from the peripheral blood of 19 women at 12½ to 17 weeks gestation were sorted. Monoclonal antibody against TfR was used to identify the presumed NRBC. The DNA in the sorted cells was amplified for the 222 bp sequence in probe Y411 as proof that the cells were derived from the fetus in male pregnancies. In 7/19 cases the 222 bp band of amplified DNA was detected on autoradiographs, consistent with the presence of male DNA in the isolated cells; 6/7 of these were confirmed as male pregnancies by karyotyping amniocytes. In the case of one female fetus, repeat studies at 32 weeks gestation and cord blood at delivery also showed the presence of the Y chromosomal sequence. This result might be explained by a low level of sex chromosome mosaicism, XX/XY chimerism (Farber, C. M., et al., Hum. Genet., 82:197-198 (1989)), or the presence of the Y411 sequence in single copy on the X chromosome or autosomes. In 10/12 cases where the 222 bp was absent, the fetuses were female. Therefore, detection of the Y chromosomal sequence was successful in 6/8 of 75% of the male-bearing pregnancies. In the two pregnancies where male DNA was not detected, there may have been fetomaternal blood group incompatibility. Alternatively, there may not have been fetomaternal hemorrhage or the number of NRBCs present may have been below the limit of sensitivity for detection of DNA. The conditions used made it possible to detect a minimum of 100 pg of fetal DNA, or the equivalent of 15 fetal cells. The limit of sensitivity can be improved by extending the number of cycles used in PCR. This work demonstrated that for the first time, fetal DNA was detected in cells isolated from maternal blood.
  • To further decrease false positive amplification and permit detection of fetal DNA at the single cell level on agarose gels, PCR is being carried out using primers derived from a single copy of sequence specific for the long arm of the Y chromosome, PY49a (Guerin, P., et al., [0103] Nucleic Acids Res., 16:7759 (1988)). In preliminary experiments using 60 cycles of PCR, Y chromosomal DNA is visible on ethidium-bromide stained agarose gels. This extraordinary degree of sensitivity will now be applied to DNA from sorted fetal cells.
    • EXAMPLE 5 Determination of the Volume, Morphology and Universality of Fetomaternal Hemorrhage
  • a. General Strategy [0104]
  • It is also possible, because of the availability of the present method of isolating fetal nucleated cells from blood obtained from a pregnant woman, to determine whether fetal cells can be found in the maternal blood in all pregnancies. A data base can be created that can provide information on the number and type of fetal cells circulating in maternal blood as pregnancy progresses. Based on previous work, it is anticipated that there will be a normal range of values that is dependent on gestational age; deviation from these values will be studied as a potential indication of a pregnancy at risk. Specifically, large amounts of fetal blood in the maternal circulation may be correlated with placental abnormalities, threatened miscarriage and intrauterine growth retardation. [0105]
  • Maternal venous blood samples are collected from pregnant women, generally prior to any invasive procedures. In general, a single 20 ml. venous blood sample will be obtained. In a subgroup of patients, permission will be sought to draw blood samples every 4 weeks to follow changes in numbers of fetal cells present. Blood is collected in EDTA, diluted 1:1 with Hanks Balanced Salt Solution (HBSS), layered over a Ficoll-Hypaque column (Pharmacia) and spun at 1400 rpm for 40 minutes at room temperature. The mononuclear cell layer will be isolated, washed twice with HBSS and stained with fluorescent monoclonal antibodies. For example, this can be a combination of fluorescein isothiocyanate-conjugated antitransferrin receptor (TfR) and phycoerythrin-conjugated anti-monocyte antibodies (M3, Becton-Dickinson catalog 17497) and anti-lymphocyte antibodies (L4, Becton Dickinson catalog #7347). The staining occurs on ice, in phosphate buffered saline (PBS) containing 2% fetal calf serum and 0.1% sodium azide. The cells are washed in PBS prior to flow cytometry. Analysis and sorting are performed on a Becton-Dickinson FACS-IV interfaced with a Consort 40 program. Data will be acquired on the relative size and fluorescence (in two colors) of the analyzed cells. Cells that are fluorescent in the green wavelength (TfR positive) and not fluorescent in the red wavelength (L4 and M3 negative) will contain the presumed fetal NRBCs. The percentage of these cells in the mononuclear cell layer are recorded and analyzed as a function of gestational age. These cells are sorted for microscopy and PCR amplification. In addition, cells that are not fluorescent in the green wavelength (TfR negative) but are fluorescent in the red wavelength (L4 and/or M3 positive) are sorted as a presumed maternal leucocyte population and source of maternal DNA polymorphisms. [0106]
  • An additional benefit of studying nucleated fetal cells in maternal blood is that the amount of fetal DNA present can be extrapolated to determine the extent of fetomaternal hemorrhage in normal and unusual pregnancies. In the pregnancies studied, an average amount of 1 ng of fetal DNA (corresponding to 150 NRBCs) was present. Using published values of the number of NRBCs per liter of fetal blood at 16 weeks, (3.6×10[0107] 9)(Millar, D. S. et al., Prenat. Diagnosis, 5:367-373 (1985); (Forestier, F., et al., Pediatr. Res., 20:342-346 (1986)) and doing simple algebra, these results were calculated to be consistent with 2-20 μl hemorrhage of fetal blood into maternal circulation. This is a trivial amount when compared with the fetoplacental blood volume at 16 weeks, about 20 ml. It is important to validate and extend these results to generate normative data regarding fetomaternal transfusion in early pregnancies. It will be equally important to correlate deviations from the expected results with pregnancy complications.
    • EXAMPLE 6 Detection of Male DNA in Cells Sorted from Pregnant Women at Different Points in Gestation
  • Venous blood samples (20 ml) were collected in EDTA from healthy women with uncomplicated pregnancies, prior to invasive diagnostic procedures, at different points in gestation. The mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation and incubated with the monoclonal antibodies fluorescein (FITC)-conjugated anti-TfR, phycoerythrin (PE)-conjugated [0108] anti-Leu 4 and PE-conjugated anti-Leu M3 (Becton-Dickinson). Dual color analysis and flow sorting were performed on a fluorescence-activated cell sorter.
  • Cells that display green fluorescence but not red fluorescence (TfR positive, [0109] Leu 4 negative, Leu M3 negative) were collected into sterile micro test tubes and frozen at −20° C. Prior to polymerase chain reaction amplification, the cells were lysed by boiling. The polymerase chain reaction (PCR) was performed under standard conditions using standard reagents as described in Example 4. The primers used to amplify material from the Y chromosome define a 397 base pair (bp) sequence. After PCR, the patient samples were analyzed with conventional Southern blots using 32P labelled probe. Ethidium bromide stained agarose gels and autoradiographs were examined for the presence of the 397 bp band, which is considered significant only if reagent controls do not reveal false positive amplification.
  • Under the reaction conditions described above, it was possible to detect the 397 bp male specific band if 5 pg of male DNA was present. This is approximately the amount of DNA present in one cell. When excess female DNA (500 ng) was added to the reaction mixture, the male specific band was consistently detectable at 100 pg. [0110]
  • FIG. 4 represents a summation of samples obtained from twelve women bearing male fetuses. These samples were taken at different times in pregnancy, and one woman was sampled twice. The data indicates that there is a relationship betwen gestational age and the detection of male DNA. This implies a potential biologic “window” for the transfer of fetal nucleated erythrocytes into the maternal circulation. [0111]
    • EXAMPLE 7 Detection of Female Fetal DNA by Amplification of Paternal Polymorphisms
  • Venous blood samples (20 ml) were collected in EDTA from health women with uncomplicated pregnancies. The mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation and incubated with the monoclonal antibodies fluorescein (FITC)-conjugated anti-TfR, phycoerythrin (PE)-conjugated [0112] anti-Leu 4 and PE-conjugated anti-Leu M3 (Becton-Dickinson). Dual color analysis and flow sorting were performed on a fluorescence-activated cell sorter.
  • Cells that display green fluorescence but not red fluorescence (TfR positive, [0113] Leu 4 negative, Leu M3 negative) were collected into sterile micro test tubes and frozen at −20° C. Additionally, cells that displayed red fluorescence but not green fluorescence (TfR negative, Leu 4 positive, Leu M3 positive) were collected in an identical manner. Prior to polymerase chain reaction (PCR) amplification, the cells were lysed by boiling. PCR was performed using buffers containing 1 mM MgCl2. The primers used in PCR amplify a highly polymorphic region of chromosome 17. Amplified DNA sequences correspond to blocks of genes transmitted directly from parent to child. As a result of the high degree of individual variation in these sequences, it is uncommon for two parents to manifest identical DNA patterns. Thus, it is possible to demonstrate inheritance of the paternal sequences in the sorted fetal cells. Since these sequences are from chromosome 17, they are independent of fetal sex, and may be used to distinguish female fetal DNA from maternal DNA. Amplified DNA was separated by electrophoresis through ethidium bromide stained agarose gels. The DNA was transferred to nylon filters and probed using 32P labeled sequence. The maternal DNA, paternal DNA TfR+ cells, and TfR− cells were then compared.
  • In 5 of 10 pregnant women, it was possible to show the presence of paternal sequences in the sorted candidate fetal cell population. In the other 5 women, no differences were seen between the maternal DNA and the DNA obtained from the candidate fetal cells. [0114]
    • EXAMPLE 8 Reconstruction Experiments Using Non-Pregnant Female Blood and Added Male Cord Blood To Simulate the Presence of Fetal Cells in Maternal Blood
  • Venous blood samples (20 ml) were collected in EDTA from healthy non-pregnant women. Umbilical cord blood samples (10 ml) were collected in EDTA from normal newborns. The mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation. Cell counts were performed with a hemocytometer. Separate aliquots of cells were made containing: 1) female cells alone; 2) female cells plus 10[0115] 2 added male cord blood cells; 3) 3 female cells plus 103 added male cord blood cells; 4) female cells plus 104 added male cord blood cells; 5) female cells plus 105 added male cord blood cells; 6) female cells plus 106 added male cord blood cells; 7) male cord blood cells alone. The separate aliquots were then incubated with the individual monoclonal antibodies being tested. Analysis and sorting were performed using a flow cytometer. For each aliquot, a bivariate histogram was obtained, and gating parameters were established for antibody positive and antibody negative cells. The sorted cells were collected into sterile micro test tubes and frozen at −20° C. PCR amplification was performed with primers that detect a 397 bp sequence unique to the Y chromosome. The presence of a band at 397 bp in autoradiographs was used to confirm the presence of male umbilical cord blood cells in sorted samples.
  • FIG. 5 shows the histograms obtained when FITC-anti transferrin receptor is used. In the non-pregnant female, 0.1% of the mononuclear cells react with the antibody. In male cord blood, 24.9% of the mononuclear cells react with the antibody. With the addition of more and more umbilical cord cells to the non-pregnant female cells, and increased percentage of cells that react with the antibody is seen. [0116]
  • FIG. 6 shows that male DNA is detected in the TfR[0117] + cells when 102-106 male cells are added. Male DNA is detected in the TfR− cells when 105-106 male cells are added. This results from the presence of male white blood cells in the TfR− population.
  • FIG. 7 shows the histograms obtained when anti HPCA-1 antibody is used. In the non-pregnant female, 0.9% of the mononuclear cells react with antibody. In umbilical cord blood, a well-defined population of cells is seen, but the percentage is only 1.1%. Thus, the addition of umbilical cord blood cells to the nonpregnant female cells is not seen on the histograms as clearly as with the transferrin receptor antibody. An increased number of HPCA[0118] + cells were collected as the amounts of added cord blood cells increased.
  • In agarose gels, the 397 bp band consistent with DNA was detected in the HPCA[0119] + cells when 103-105 male cells were added to the female cells. Male DNA was detected in agarose gels in the HPCA cells when 106 male cells were added to the female cells.
    • EXAMPLE 9 In situ Hybridization Using Molecular Probes Recognizing Individual Chromosomes in Flow Sorted Nucleated Erythrocytes
  • To demonstrate diagnostic utility of the present invention, a DNA probe set was constructed of chromosome specific probes that provided both good signal to noise ratios and good spatial resolution of the fluorescent signals. Accordingly, specific probes were developed for five chromosomes frequently seen as liveborn aneuploidies; [0120] chromosomes 13, 18, 21, X and Y. A probe for chromosome 1 was used as a control. In constructing the probes, the general strategy was to identify a starting clone that mapped to the desired chromosomal region by multiple genetic and physical methods, and then to use that clone to identify a matching cosmid “contig” which was then used as a hybridization probe.
  • Hybridization of the high copy number repeat sequences was suppressed by inclusion of total genomic human DNA, and the chromosomal specificity verified by hybridization to metaphase spreads. The probes gave sharp, punctate fluorescent signals in interphase cells that were easily discriminated and enumerated. The Y probe used in this study was pDP97, a repetitive clone (a 5.3 kb EcoRI Y fragment from cosmid Y97 subcloned into EcoRI site of pUC-13). All probes were labeled with biotin, hybridized under suppression conditions, and specific hybridization detected by conjugated streptoavidin-FITC, which showed as a single “dot” in the FITC image. As illustrated in FIG. 8, the Y chromosome was detected by in situ hybridization of a pDP97 probe for the Y chromosome in a fetal nucleated red blood cell. Thus, prenatal diagnosis for chromosomal abnormalities could be performed on fetal cells isolated from maternal blood. [0121]
    • EXAMPLE 10 Detection of Fetal Hematopoietic Stem Cells in Maternal Circulation
  • Venous blood samples (20 ml) were collected in EDTA or citrate dextrose from healthy women with uncomplicated pregnancies, prior to invasive diagnostic procedures, at different points in gestation. The mononuclear cell layer was isolated by Ficoll/Hypaque density centrifugation and incubated with monoclonal antibodies directed against antigens expressed on the cell surface of hematopoietic progenitor cell. These antibodies are described in Example 2. The antibodies were either directly or indirectly conjugated to a fluorescent dye. Analysis and flow sorting of fluorescent cells were performed on a fluorescence-activated cell sorter. Fluroescent cells are cells that have bound antibody recognizing primitive cell surface antigens; thus, they are hematopoietic precursor cells. These cells were physically sorted into sterile micro test tubes and frozen at −20° C. Prior to polymerase chain reaction amplification, the cells were lysed by boiling. The polymerase chain reaction (PCR) was performed under standard conditions using standard reagents. The primers selected amplified material from the Y chromosome as a means of detecting male fetal cells. These primers defined a 397 base pair sequence. After PCR, the patient samples were analyzed with conventional Southern blots using a [0122] 32P labeled probe. Ethidium bromide stained agarose gels and autoradiographs were examined for the presence of the amplified 397 bp band, which was considered significant only if reagent controls did not reveal false positive amplification.
  • Twenty five women were studied with antibody to a human progenitor cell antigen (HPA). This antigen has been given a cluster of differentiation (CD) designation as CD34. Cells that are CD34+ are undifferentiated and represent hematopoietic stem cells. Eleven of the twenty five women whose peripheral blood was sorted have confirmed male pregnancies. In 8/11 (72%) of those women, male DNA was detected in the sorted CD34+ cells. This confirms that fetal hematopoietic stem cells are circulating in mother's blood. [0123]
  • Additionally, antibodies were used against the oncofetal antigen expressed in many leukemias (CALLA) to detect fetal lymphoblasts in the maternal circulation. This antibody is designated as CD10. Seventeen women have been sorted with antibody to CD10. In 8/17, evidence of male fetal DNA has been detected in CD10+ cells. [0124]
    • EXAMPLE 11 Additional Antibodies to Detect Fetal Hematopoietic Cells in Maternal Circulation
  • Human fetal umbilical cord blood is being used as a source of mononuclear cells for study of fetal cell populations, in order to determine additional antibodies to detect fetal hematopoietic cells in material circulation. Pure fetal blood samples were tested from as early as 19 weeks gestation. [0125]
  • The mononuclear cell layer is isolated as described in example 10. Mononuclear cells are incubated with mouse monoclonal antibodies to human stem cell antigens (CD34, CD10, CD38, which recognizes myeloblasts, CD33, HLA-DR, CD36, glycophorin A, CD71, 8G12, THB-7 and others). Many of these antibodies are available directly conjugated to a fluorescent dye. If the antibody is not fluorescent, a sandwich technique is used to attach fluorescein-conjugated goat anti mouse antibody to the primary antibody. [0126]
  • Our data thus far has demonstrated that there are differences in the types of fetal cells present as the pregnancy proceeds. Approximately 4% of the fetal mononuclear cells are CD10+ until 34 weeks gestation. CD10+ cells are not detectable at term. Approximately 5% of fetal mononuclear cells are CD34+. Between 8 and 18% of fetal mononuclear cells are CD38+. The percentages of CD38+ cells increase during the pregnancy. Therefore, varying the type of antibody used in cell separation based on the length of gestation may help increase the isolation of fetal cells. [0127]
    • EXAMPLE 12 Detection of Y Chromosomal DNA Sequences in Venous Blood Samples Obtainly Only from Women Having Male Fetuses
  • Venous blood samples (20 ml) were collected in EDTA or citrate dextrose from healthy women with uncomplicated pregnancies, prior to invasive diagnostic procedures, at different points in gestation. The mononuclear cell layer was isolated as described in Example 10. Alternatively, mononuclear cells cobld be obtained by (nonnucleated) red cell lysis buffers. In this example, the specific monoclonal antibodies chosen to label the fetal cells of interest are CD36 and glycophorin A, used singly or in combination. These antibodies are either directly or indirectly conjugated to a fluorescent dye. CD36 recognizes a cell surface antigen present on nucleated erythrocytes and monocytes, whereas glycophorin A recognizes an antigen present on erythrocytes. Fluorescent cells that have bound either or both antibodies were flow sorted; such cells were frozen and subsequently amplified for Y chromosomal sequences by the polymerase chain reaction as described in Example 10. [0128]
  • In a group of 18 women studies, 11 had male fetuses and 7 had female fetuses. Y chromosomal DNA sequences were detected in the cells sorted with CD36 and/or glycophorin A antibodies in 10/11 (91%) of the women having males. None of the women bearing females (0/7) had Y chromosomal DNA sequences detected. The probability of obtaining these results by chance, p=0.00025 by Fisher exact test. Thus, the antibodies CD36 and glycophorin A are particularly effective in identifying fetal nucleated cells circulating in maternal blood. [0129]
    • EXAMPLE 13 Detection of Fetal Cells with 47 XY +21 Karotype in Maternal Peripheral Blood
  • A peripheral blood sample (20 ml.) was obtained from a pregnant woman at nineteen weeks of gestation. A previous ultrasound examination performed at 17 weeks gestation revealed fetal malformations consistent with a diagnosis of Down Syndrome. An amniocentesis was performed for fetal chromosome analysis and results of the karotype were 47, XY, +21. [0130]
  • Flow Cytometry [0131]
  • The woman's venous blood was collected in ethylenediamine tetraacetic acid (EDTA), diluted 1:3 with Hanks' balanced salt solution, layered over a Ficoll/Hypaque column (Pharmacia) and spun at 2000 rpm for twenty minutes at room temperature. The mononuclear cell layer was isolated, washed with phosphate buffered saline (PBS) and centrifuged at 1400 rpm for ten minutes at 4° C. The cell pellet was incubated with a 1:10 dilution of fluorescein-conjugated anti-TfR (anti CD 71) Becton-Dickinson Catalog No. 7513) in PBS on ice for thirty minutes. The cells were washed once in PBS prior to flow sorting. [0132]
  • Analysis and sorting were performed on a Becton-Dickinson FACS IV with a Consort 40 program as described (Bianchi et al., [0133] Cytometry 8:197-202 (1987)). The gain was standardized manually using fluorescent beads and a fluorescein isothiocyanate (FITC) conjugated antibody control, keyhole limpet hemocyanin, an antigen not expressed on human cells (Becton-Dickinson Catalog No. 9041). A small aliquot of the woman's mononuclear cells were incubated with the antibody control to determine background fluorescence. TfR+ (fluorescent) and TfR− (non-fluorescent) cells were determined by physical separation on a logarithmic scale and sorted into 1.5 ml centrifuge tubes.
  • Fluorescence in Situ Hybridization [0134]
  • A solution of methanol and acetic acid (3:1) was used to fix nuclei from sorted cells to glass slides which were then stored at −20° C. (Klinger et al., [0135] Am. J. Hum. Genet. 51:55-65 (1992)). The contents of the entire forementioned Klinger et al. reference is expressly incorporated by reference. Prior to hybridization, slides were warmed briefly at 60° C. Control hybridizations with male lymphocytes were performed concurrently.
  • The probe sets used for hybridization to the Y chromosome and to [0136] chromosome 21 have been described previously (Klinger et al., cited supra, (1992)). The Y chromosome probe was labeled with biotin-dUTP (Sigma) and the chromosome 21 probe was labeled with digoxigenin-dUTP (Boehringer Mannheim). The probes were hybridized simultaneously under suppression conditions (Cremer et al., Hum Genet 80:235-246 (1988); Lichter et al., Hum Genet 80:224-234 (1988)). The Y chromosome probe was detected with avidin conjugated to Texas Red (Vector Laboratories) and the chromosome 21 probe was detected with anti-digoxigenin conjugated to fluorescein isothiocyanate (FITC) (Boehringer Mannheim). The slides were mounted in 2.33% DABCO (1,4-diazobicyclo[2.2.2]octane) (Sigma) in 100 mM Tris-HCl, pH 8.0, 90% (v/v) glycerol with 0.5 ug/ml 4,6-diamidino-2-phenyl-indole (DAPI) as a counterstain (Sigma). Slides were analyzed using a Zeiss Axioplan epifluorescence microscope. FITC and Texas Red were monitored simultaneously using a dual band pass filter set (Omega Optical, Inc., Brattleboro, Vt.). Images were captured with a cooled confocal digital camera (Photometrics Ltd., Tucson, Ariz.) and image processing was performed with software developed by Recognition Technology, Inc., (Westboro, Mass.).
  • The results of the contour plot depicting fluorescence intensity versus light scatter are shown in FIG. 9. The percentage of TfR[0137] + cells was 1.3. A total of approximately 43,000 TfR+ cells and 300,000 TfR− cells were sorted.
  • In situ hybridization studies performed on the TfR[0138] − cells revealed the presence of numerous nuclei. Control slides prepared from male lymphocytes gave bright signals with both the 21 and Y probes. The nuclei from TfR− cells that hybridized to the probes were exclusively maternal, with two signals for chromosome 21 and no signal with the Y. The majority of the sorted cells in the TfR+ fraction did not hybridize, due to the fact that most of them were reticulocytes, which are anucleate. Most of the nuclei present were in a few giant clumps that had retained large amounts of cytoplasm. Of the few TfR+ cells that did hybridize, FITC and Texas Red signals were generally weak. There were three nuclei with one Texas Red and three FITC signals, consistent with the presence of one Y chromosome and three copies of chromosome 21 (FIG. 10). The remainder of the data are summarized as follows.
    Results of hybridization studies on scored cells:
    Texax Red (Y) FITC (21) Number of Cells
    Number
    1 3 3
    of signals 1 0 8
    0 3 1
    1 1 1
    13
    Uninformative 15
    28
  • Equivalents [0139]
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. [0140]

Claims (45)

1. A method of detecting the presence or absence of a fetal DNA sequence of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman, comprising:
obtaining a sample of peripheral blood from a pregnant woman;
treating the sample of peripheral blood such that fetal DNA present in fetal nucleated cells present in the sample is made available for detection resulting in available fetal DNA; and
detecting the presence or absence of a fetal DNA sequence of interest in the available fetal DNA.
2. The method as claimed in claim 1 wherein the proportion of fetal nucleated cells present in the sample of peripheral blood obtained from the pregnant woman is increased forming a sample enriched in fetal nucleated cells prior to the detection step.
3. The method of claim 1 wherein the sample enriched in fetal nucleated cells is formed by separating the non-nucleated cells from the nucleated in the peripheral blood sample forming a nucleated cell enriched sample and by treating the nucleated cell enriched sample such that the proportion of fetal cells in the sample is increased forming a fetal nucleated cell enriched sample.
4. The method of claim 1 wherein the fetal DNA is amplified prior to the detection step resulting in amplified fetal DNA.
5. A method of detecting the presence or absence of fetal DNA of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman, comprising:
obtaining a sample of peripheral blood from the woman;
treating the sample of peripheral blood such that fetal DNA present in fetal nucleated cells present in the sample is made available for hybridization with a DNA probe resulting in available fetal DNA;
contacting the available fetal DNA with a DNA probe hybridizable to fetal DNA of interest under hybridization conditions; and
detecting the presence or absence of hybridization between the DNA probe and the fetal DNA of interest as an indication of the presence or absence of the fetal DNA of interest.
6. The method of claim 5 wherein the fetal nucleated cells in the treating step are undifferentiated hematopoietic cells.
7. The method of claim 5 wherein the fetal nucleated cells are selected from the group consisting of erythroblasts, lymphoblasts, and myeloblasts.
8. The method of claim 6 wherein the undifferentiated hematopoietic cells are erythroid cells.
9. The method of claim 8 wherein the undifferentiated erythroid cells are fetal nucleated erythrocytes.
10. The method of claim 5 wherein the proportion of fetal nucleated cells present in the sample of peripheral blood obtained from the pregnant woman is increased forming a sample enriched in fetal nucleated cells prior to the detection step.
11. The method of claim 10 wherein the sample enriched in fetal nucleated cells is formed by separating non-nucleated cells from nucleated cells in the peripheral blood sample forming a nucleated cell enriched sample and by treating the nucleated cell enriched sample such that the proportion of fetal cells in the sample is increased forming a fetal nucleated cell enriched sample.
12. The method of claim 5 wherein the fetal DNA of interest in the contacting and detecting steps is Y chromosomal DNA.
13. The method of claim 5 wherein the hybridization in the detecting step is between the DNA probe and a disease causing mutation.
14. The method of claim 13 wherein the disease causing mutation is a cystic fibrosis-causing mutation.
15. The method of claim 13 wherein the disease causing mutation is a Duchenne muscular dystrophy-causing mutation.
16. The method of claim 13 wherein the disease causing mutation is a hemophilia A-causing mutation.
17. The method of claim 13 wherein the disease causing mutation is a Gaucher disease-causing mutation.
18. The method of claim 13 wherein the disease causing mutation is a sickle cell anemia-causing mutation.
19. The method of claim 13 wherein the hybridization in the detecting step is between the DNA probe and a fetal DNA of interest selected for assessing a chromosomal abnormality.
20. The method of claim 5 wherein the hybridization in the detecting step is in situ hybridization.
21. The method of claim 6 wherein the hybridization in the detecting step is in situ hybridization.
22. The method of claim 9 wherein the hybridization in the detecting step is in situ hybridization.
23. The method of claim 12 wherein the hybridization in the contacting step is in situ hybridization.
24. The method of claim 5 wherein the fetal DNA is amplified prior to the detection step resulting in amplified fetal DNA.
25. The method of claim 6 wherein the fetal DNA is amplified prior to the detection step resulting in amplified fetal DNA.
26. The method of claim 9 wherein the fetal DNA is amplified prior to the detection step resulting in amplified fetal DNA.
27. The method of claim 3 further comprising determining the gestational age at the time the sample of peripheral blood is obtained and treating the sample such that fetal DNA present in a selected type of fetal nucleated cells is made available for hybridization, said type of fetal nucleated cell being selected based upon the known presence of such fetal nucleated cells in the peripheral blood of a pregnant woman at the determined gestational age.
28. The method of claim 5 further comprising the step of treating the peripheral blood sample to remove residual fetal nucleated cells from a previous pregnancy prior to the detection step.
29. The method of claim 5 wherein the peripheral blood sample in the obtaining step is obtained between about ten and about nineteen weeks gestation.
30. A method of detecting a fetal DNA sequence of interest in fetal DNA derived from a sample of peripheral blood obtained from a pregnant woman, comprising:
obtaining a sample of peripheral blood from a pregnant woman;
separating fetal nucleated cells from the peripheral blood onto a solid support forming immobilized fetal nucleated material;
contacting the immobilized fetal nucleated material with a DNA probe hybridizable to fetal DNA of interest under hybridization conditions; and
detecting the presence of hybridization between the DNA probe and the fetal DNA of interest as an indication of the presence or absence of the fetal DNA of interest.
31. The method of claim 30 wherein the hybridization in the detecting step is in situ hybridization.
32. The method of claim 31 wherein the hybridization of high copy number repeat sequences present in the fetal DNA is suppressed in the contacting step.
33. A method for determining the sex of a fetus, comprising:
obtaining a sample of peripheral blood from a woman pregnant with a fetus;
treating the sample of peripheral blood such that fetal DNA present in fetal nucleated cells present in the sample is made available for hybridization resulting in available fetal DNA;
contacting the available fetal DNA with a DNA probe hybridizable to fetal Y chromosomal DNA under hybridization conditions; and
detecting the presence of hybridization between the DNA probe and the fetal Y chromosomal DNA as an indication of a male fetua or the absence of hybridization as an indication of a female fetus.
34. A method for diagnosing a disease in a fetus, comprising:
obtaining a sample of peripheral blood from a woman pregnant with a fetus;
treating the sample of peripheral blood such that fetal DNA present in fetal nucleated cells present in the peripheral sample is made available for hybridization resulting in available fetal DNA;
contacting the available DNA with a DNA probe hybridizable to fetal DNA of interest associated with a disease under hybridization conditions; and
detecting the presence or absence of hybridization between the DNA probe and the fetal DNA of interest associated with the disease as an indication that the fetus has the disease.
35. A method for detecting a chromosomal abnormality in a fetus, comprising:
obtaining a sample of peripheral blood from a woman pregnant with a fetus;
separating fetal nucleated cells from the peripheral blood sample onto a solid support forming immobilized fetal nucleated material;
contacting the immobilized fetal nucleated materail with a DNA probe hybridizable to chromosomal fetal DNA of interest under hybridization conditions; and
detecting the presence or absence of hybridization between the DNA probe and the chromosomal fetal DNA of interest as an indication of the presence or absence of a chromosomal abnormality.
36. The method of claim 35 wherein the hybridization in the detecting step is in situ hybridization.
37. The method of claim 36 wherein the chromosomal abnormality is a chromosomal aneuploidy.
38. The method of claim 37 wherein the chromosomal aneuploidy is trisomy 21.
39. The method of claim 37 wherein the chromosomal aneuploidy is trisomy 18.
40. The method of claim 37 wherein the chromosomal aneuploidy is trisomy 13.
41. A method for determining whether a pregnancy is at risk, comprising:
obtaining a peripheral blood sample from a pregnant woman at a selected gestational age;
detecting the number of fetal cells present in the peripheral blood sample;
comparing the number of fetal cells detected to a standard to determine whether the number of fetal cells is indicative of a pregnancy at risk, said standard being selected based on the number of fetal cells present in a peripheral blood sample obtained from a woman having a normal pregnancy at the selected gestational age.
42. A method of increasing the proportion of fetal nucleated cells present in a peripheral blood sample containing nucleated and non-nucleated cells, comprising:
separating non-nucleated cells from nucleated cells present in a peripheral blood sample forming a nucleated cell enriched sample; and
treating the nucleated cell enriched sample such that the proportion of fetal cells in the sample is increased forming a fetal nucleated cell enriched sample.
43. The method of claim 42 wherein the separating step is a density gradient centrifugation.
44. The method of claim 42 wherein the nucleated enriched sample is treated by contacting the sample with (i) a first monoclonal antibody which recognizes fetal nucleated cells but not maternal cells and/or (ii) a second monoclonal antibody which recognizes maternal cells but not fetal nucleated cells, under conditions appropriate for antibody binding thereby producing (i) fetal nucleated cell-first monoclonal antibody complexes and/or (ii) maternal cell-second monoclonal antibody complexes, respectively, and
(i) separating fetal nucleated cell-first monoclonal antibody complexes from maternal cells and/or
(ii) separating maternal cell-second monoclonal antibody complexes from fetal nucleated cells thereby separating fetal nucleated cells from maternal cells.
45. The method of claim 43 wherein the nucleated enriched sample is treated by contacting the sample with (i) a first monoclonal antibody which recognizes fetal nucleated cells but not maternal cells and/or (ii) a second monoclonal antibody which recognizes maternal cells but not fetal nucleated cells, under conditions appropriate for antibody binding producing (i) fetal nulceated cell-first monoclonal antibody complexes and/or (ii) maternal cell-second monoclonal antibody complexes, respectively and,
(i) separating fetal nucleated cell-first monoclonal antibody complexes from maternal cells and/or
(ii) separating maternal cell-second monoclonal antibody complexes from fetal nucleated cells thereby separating fetal nucleated cells from maternal cells.
US09/827,853 1989-11-13 2001-04-05 Non-invasive method for isolation and detection of fetal DNA Abandoned US20020006621A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/827,853 US20020006621A1 (en) 1989-11-13 2001-04-05 Non-invasive method for isolation and detection of fetal DNA
US10/113,177 US20020137088A1 (en) 1989-11-13 2002-03-28 Non-invasive method for isolation and detection of fetal DNA
US10/374,705 US20040018509A1 (en) 1989-11-13 2003-02-25 Non-invasive method for isolation and detection of fetal DNA
US11/051,982 US20060051775A1 (en) 1989-11-13 2005-02-04 Non-invasive method for isolation and detection of fetal DNA
US11/283,500 US20070015171A1 (en) 1989-11-13 2005-11-17 Non-invasive method for isolation and detection of fetal DNA
US12/008,549 US20080182261A1 (en) 1989-11-13 2008-01-11 Non-invasive method for isolation and detection of fetal DNA

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43605789A 1989-11-13 1989-11-13
US70639391A 1991-05-28 1991-05-28
US77268991A 1991-10-07 1991-10-07
US95773692A 1992-10-07 1992-10-07
US08/338,279 US5641628A (en) 1989-11-13 1994-11-14 Non-invasive method for isolation and detection of fetal DNA
US47063395A 1995-06-06 1995-06-06
US09/827,853 US20020006621A1 (en) 1989-11-13 2001-04-05 Non-invasive method for isolation and detection of fetal DNA

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US47063395A Continuation 1989-11-13 1995-06-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/113,177 Continuation US20020137088A1 (en) 1989-11-13 2002-03-28 Non-invasive method for isolation and detection of fetal DNA

Publications (1)

Publication Number Publication Date
US20020006621A1 true US20020006621A1 (en) 2002-01-17

Family

ID=27503847

Family Applications (7)

Application Number Title Priority Date Filing Date
US08/338,279 Expired - Lifetime US5641628A (en) 1989-11-13 1994-11-14 Non-invasive method for isolation and detection of fetal DNA
US09/827,853 Abandoned US20020006621A1 (en) 1989-11-13 2001-04-05 Non-invasive method for isolation and detection of fetal DNA
US10/113,177 Abandoned US20020137088A1 (en) 1989-11-13 2002-03-28 Non-invasive method for isolation and detection of fetal DNA
US10/374,705 Abandoned US20040018509A1 (en) 1989-11-13 2003-02-25 Non-invasive method for isolation and detection of fetal DNA
US11/051,982 Abandoned US20060051775A1 (en) 1989-11-13 2005-02-04 Non-invasive method for isolation and detection of fetal DNA
US11/283,500 Abandoned US20070015171A1 (en) 1989-11-13 2005-11-17 Non-invasive method for isolation and detection of fetal DNA
US12/008,549 Abandoned US20080182261A1 (en) 1989-11-13 2008-01-11 Non-invasive method for isolation and detection of fetal DNA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/338,279 Expired - Lifetime US5641628A (en) 1989-11-13 1994-11-14 Non-invasive method for isolation and detection of fetal DNA

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/113,177 Abandoned US20020137088A1 (en) 1989-11-13 2002-03-28 Non-invasive method for isolation and detection of fetal DNA
US10/374,705 Abandoned US20040018509A1 (en) 1989-11-13 2003-02-25 Non-invasive method for isolation and detection of fetal DNA
US11/051,982 Abandoned US20060051775A1 (en) 1989-11-13 2005-02-04 Non-invasive method for isolation and detection of fetal DNA
US11/283,500 Abandoned US20070015171A1 (en) 1989-11-13 2005-11-17 Non-invasive method for isolation and detection of fetal DNA
US12/008,549 Abandoned US20080182261A1 (en) 1989-11-13 2008-01-11 Non-invasive method for isolation and detection of fetal DNA

Country Status (1)

Country Link
US (7) US5641628A (en)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101387A2 (en) * 2001-06-08 2002-12-19 Consiglio Nazionale Delle Ricerche A non invasive method for screening and diagnosis fetal aneuploidies
US20040166555A1 (en) * 1999-11-10 2004-08-26 Rebecca Braff Cell sorting apparatus and methods for manipulating cells using the same
US20070026414A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026416A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026381A1 (en) * 2005-04-05 2007-02-01 Huang Lotien R Devices and methods for enrichment and alteration of cells and other particles
US20070026413A1 (en) * 2005-07-29 2007-02-01 Mehmet Toner Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026415A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070059719A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Business methods for prenatal Diagnosis
US20070059683A1 (en) * 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
US20070059680A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for cell enrichment
US20070059781A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for size based separation and analysis
US20070059774A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Kits for Prenatal Testing
US20070099207A1 (en) * 2005-04-05 2007-05-03 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070160503A1 (en) * 2003-06-13 2007-07-12 Palaniappan Sethu Microfluidic systems for size based removal of red blood cells and platelets from blood
US20070259424A1 (en) * 2002-09-27 2007-11-08 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US20080050739A1 (en) * 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20090181421A1 (en) * 2005-07-29 2009-07-16 Ravi Kapur Diagnosis of fetal abnormalities using nucleated red blood cells
US20090317817A1 (en) * 2008-03-11 2009-12-24 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US20100105049A1 (en) * 2008-09-16 2010-04-29 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US20100112575A1 (en) * 2008-09-20 2010-05-06 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing
US20100196897A1 (en) * 2007-05-04 2010-08-05 Silicon Biosystems S.P.A. Method and Device for Non-Invasive Prenatal Diagnosis
US20100216153A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20100216151A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20100273165A1 (en) * 2008-09-16 2010-10-28 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US20100291572A1 (en) * 2006-06-14 2010-11-18 Artemis Health, Inc. Fetal aneuploidy detection by sequencing
US20100304978A1 (en) * 2009-01-26 2010-12-02 David Xingfei Deng Methods and compositions for identifying a fetal cell
US20110151610A1 (en) * 2009-12-23 2011-06-23 Varian Semiconductor Equipment Associates, Inc. Workpiece patterning with plasma sheath modulation
WO2011087760A3 (en) * 2009-12-22 2011-11-10 Sequenom, Inc. Processes and kits for identifying aneuploidy
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8450061B2 (en) 2011-04-29 2013-05-28 Sequenom, Inc. Quantification of a minority nucleic acid species
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US9217131B2 (en) 2010-01-21 2015-12-22 Biocep Ltd. Magnetic separation of rare cells
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10424394B2 (en) 2011-10-06 2019-09-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10438691B2 (en) 2013-10-07 2019-10-08 Sequenom, Inc. Non-invasive assessment of chromosome alterations using change in subsequence mappability
US10482994B2 (en) 2012-10-04 2019-11-19 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10497462B2 (en) 2013-01-25 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10622094B2 (en) 2013-06-21 2020-04-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10699800B2 (en) 2013-05-24 2020-06-30 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10930368B2 (en) 2013-04-03 2021-02-23 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10964409B2 (en) 2013-10-04 2021-03-30 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11004537B2 (en) 2011-06-24 2021-05-11 Sequenom, Inc. Methods and processes for non invasive assessment of a genetic variation
US11001884B2 (en) 2011-10-06 2021-05-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US11200963B2 (en) 2016-07-27 2021-12-14 Sequenom, Inc. Genetic copy number alteration classifications
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11694768B2 (en) 2017-01-24 2023-07-04 Sequenom, Inc. Methods and processes for assessment of genetic variations
US11697849B2 (en) 2012-01-20 2023-07-11 Sequenom, Inc. Methods for non-invasive assessment of fetal genetic variations that factor experimental conditions
US11783911B2 (en) 2014-07-30 2023-10-10 Sequenom, Inc Methods and processes for non-invasive assessment of genetic variations

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115709B1 (en) * 1986-01-16 2006-10-03 The Regents Of The University Of California Methods of staining target chromosomal DNA employing high complexity nucleic acid probes
US5641628A (en) * 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
US6509192B1 (en) * 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
GB9425138D0 (en) * 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
ATE308755T1 (en) * 1997-03-08 2005-11-15 Univ Dundee PRENATAL DIAGNOSTIC PROCEDURES IN VITRO
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
AUPO931997A0 (en) * 1997-09-22 1997-10-09 Flinders Technologies Pty Ltd Enrichment and identification of trophoblast cells in maternal peripheral blood
ATE218140T1 (en) * 1997-12-06 2002-06-15 Dna Res Innovations Ltd ISOLATION OF NUCLEIC ACIDS
US6914137B2 (en) * 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
US6677123B1 (en) * 1998-02-03 2004-01-13 Wako Pure Chemical Industries, Ltd. Process for detecting increased risk of fetal chromosomal abnormality
US6911313B2 (en) * 1998-02-06 2005-06-28 Sysmex Corporation Process for discriminating and counting erythroblasts
FR2781055B1 (en) * 1998-07-09 2000-10-13 Immunotech Sa REAGENT AND METHOD FOR PERMEABILIZATION AND IDENTIFICATION OF ERYTHROCYTES
US6414133B1 (en) * 1998-10-13 2002-07-02 Ventana Medical Systems, Inc. Multiple fusion probes
CA2362251C (en) 1999-02-25 2008-06-17 Exact Sciences Corporation Methods for preserving dna integrity
AU767983B2 (en) * 1999-04-09 2003-11-27 Esoterix Genetic Laboratories, Llc Methods for detecting nucleic acids indicative of cancer
EP1203227A4 (en) * 1999-06-04 2003-01-02 Bioseparations Inc System and method for prenatal diagnostic screening
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US20060128006A1 (en) * 1999-11-10 2006-06-15 Gerhardt Antimony L Hydrodynamic capture and release mechanisms for particle manipulation
JP2003516138A (en) * 1999-12-07 2003-05-13 エグザクト サイエンシーズ コーポレイション Detection of aerobic digestive neoplasms in the colon
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
GB0013658D0 (en) * 2000-06-05 2000-07-26 Dynal Asa Nucleic acid isolation
US7083924B2 (en) * 2000-07-10 2006-08-01 Btg International Limited Diagnostic method for the identification of foetal DNA in a material sample
EP1172445A1 (en) * 2000-07-14 2002-01-16 Praenadia GmbH A method for direct genetic analysis of target cells by using fluorescence probes
CA2428757A1 (en) * 2000-11-15 2002-07-18 Roche Diagnostics Corporation Methods and reagents for identifying rare fetal cells in the maternal circulation
CN100494360C (en) 2001-03-22 2009-06-03 博奥生物有限公司 Process for separating cells and its application
FR2824144B1 (en) * 2001-04-30 2004-09-17 Metagenex S A R L METHOD OF PRENATAL DIAGNOSIS ON FETAL CELLS ISOLATED FROM MATERNAL BLOOD
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
US8986944B2 (en) * 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
AU2003202026A1 (en) 2002-01-16 2003-09-02 Dynal Biotech Asa Method for isolating nucleic acids and protein from a single sample
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
AU2003213107A1 (en) 2002-02-15 2003-09-09 Exact Sciences Corporation Methods for analysis of molecular events
NZ535045A (en) * 2002-03-01 2008-04-30 Ravgen Inc Rapid analysis of variations in a genome
US6977162B2 (en) * 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
US7727720B2 (en) * 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US7442506B2 (en) * 2002-05-08 2008-10-28 Ravgen, Inc. Methods for detection of genetic disorders
US20070178478A1 (en) * 2002-05-08 2007-08-02 Dhallan Ravinder S Methods for detection of genetic disorders
US20040088189A1 (en) * 2002-11-06 2004-05-06 Veome Edmond A. System and method for monitoring , reporting, managing and administering the treatment of a blood component
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
WO2004077021A2 (en) * 2003-02-27 2004-09-10 Lesko Stephen A Standardized evaluation of therapeutic efficacy based on cellular biomarkers
SG173221A1 (en) * 2003-02-28 2011-08-29 Ravgen Inc Methods for detection of genetic disorders
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
US8529744B2 (en) 2004-02-02 2013-09-10 Boreal Genomics Corp. Enrichment of nucleic acid targets
CA2552262C (en) 2004-02-02 2016-04-19 The University Of British Columbia Scodaphoresis and methods and apparatus for moving and concentrating particles
US10337054B2 (en) 2004-02-02 2019-07-02 Quantum-Si Incorporated Enrichment of nucleic acid targets
US8518228B2 (en) 2011-05-20 2013-08-27 The University Of British Columbia Systems and methods for enhanced SCODA
JP2007533305A (en) * 2004-03-03 2007-11-22 ザ ジェネラル ホスピタル コーポレーション Magnetic apparatus for isolating cells and biomolecules in a microfluidic environment
US20060121624A1 (en) * 2004-03-03 2006-06-08 Huang Lotien R Methods and systems for fluid delivery
WO2005084380A2 (en) * 2004-03-03 2005-09-15 The General Hospital Corporation System for delivering a diluted solution
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
CA2570395A1 (en) * 2004-06-14 2005-12-29 The Board Of Trustees Of The University Of Illinois Antibodies binding to cd34+/cd36+ fetal but not to adult cells
ITBO20040420A1 (en) * 2004-07-07 2004-10-07 Type S R L METAL CUTTING AND FORMING MACHINE
US7439062B2 (en) * 2004-12-23 2008-10-21 Biocept, Inc. Beads for capturing target cells from bodily fluid
FR2880897B1 (en) * 2005-01-18 2010-12-17 Inst Nat Sante Rech Med METHOD OF DETECTION, NON-INVASIVE, PRENATAL, IN VITRO OF NORMAL HEALTHY CONDITION, HEALTHY CARRIER STATUS OR SICK CARRIER STATUS OF MUCOVISCIDOSIS
EP1859050B1 (en) * 2005-03-18 2012-10-24 The Chinese University Of Hong Kong A method for the detection of chromosomal aneuploidies
EP2477029A1 (en) * 2005-06-02 2012-07-18 Fluidigm Corporation Analysis using microfluidic partitioning devices
ITBO20050481A1 (en) * 2005-07-19 2007-01-20 Silicon Biosystems S R L METHOD AND APPARATUS FOR THE HANDLING AND / OR IDENTIFICATION OF PARTICLES
US20070059716A1 (en) * 2005-09-15 2007-03-15 Ulysses Balis Methods for detecting fetal abnormality
US20070059718A1 (en) * 2005-09-15 2007-03-15 Mehmet Toner Systems and methods for enrichment of analytes
US20100035246A1 (en) * 2005-10-21 2010-02-11 Avner Lushi Methods and Kits for Analyzing Genetic Material of a Fetus
ITBO20050646A1 (en) * 2005-10-26 2007-04-27 Silicon Biosystem S R L METHOD AND APPARATUS FOR CHARACTERIZATION AND COUNTING OF PARTICLES
DK2385143T3 (en) * 2006-02-02 2016-09-19 Univ Leland Stanford Junior Non-invasive fetal genetic screening by digital analysis
MX2008011406A (en) * 2006-03-06 2008-11-18 Univ Columbia Specific amplification of fetal dna sequences from a mixed, fetal-maternal source.
ITTO20060226A1 (en) 2006-03-27 2007-09-28 Silicon Biosystem S P A METHOD AND APPARATUS FOR PROCESSING AND OR ANALYSIS AND OR SELECTION OF PARTICLES, IN PARTICULAR BIOLOGICAL PARTICLES
US20070243549A1 (en) * 2006-04-12 2007-10-18 Biocept, Inc. Enrichment of circulating fetal dna
US20080124721A1 (en) * 2006-06-14 2008-05-29 Martin Fuchs Analysis of rare cell-enriched samples
AU2013204127B2 (en) * 2006-06-14 2015-07-16 Artemis Health, Inc. Rare cell analysis using sample splitting and DNA tags
EP2366801B1 (en) * 2006-06-14 2016-10-19 Verinata Health, Inc Methods for the diagnosis of fetal abnormalities
EP3424598B1 (en) * 2006-06-14 2022-06-08 Verinata Health, Inc. Rare cell analysis using sample splitting and dna tags
WO2008008515A2 (en) * 2006-07-14 2008-01-17 Aviva Biosciences Corporation Methods and compositions for detecting rare cells from a biological sample
US20080117416A1 (en) * 2006-10-27 2008-05-22 Hunter Ian W Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same
WO2008122960A2 (en) * 2007-04-10 2008-10-16 Microvacuum Ltd. Label-free optical detection method
US20100112590A1 (en) 2007-07-23 2010-05-06 The Chinese University Of Hong Kong Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment
CN106834474B (en) 2007-07-23 2019-09-24 香港中文大学 Utilize gene order-checking diagnosing fetal chromosomal aneuploidy
WO2009046447A1 (en) * 2007-10-06 2009-04-09 Katalin Polgar Fetal open lesion detection system
ITTO20070771A1 (en) 2007-10-29 2009-04-30 Silicon Biosystems Spa METHOD AND APPARATUS FOR IDENTIFICATION AND HANDLING OF PARTICLES
US20110143340A1 (en) * 2007-11-01 2011-06-16 Biocept, Inc. Non-invasive isolation of fetal nucleic acid
EP2238434A4 (en) 2008-02-01 2011-06-22 Univ British Columbia Methods and apparatus for particle introduction and recovery
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory
US20100159506A1 (en) * 2008-07-25 2010-06-24 Cellscape Corporation Methods and systems for genetic analysis of fetal nucleated red blood cells
US20100240054A1 (en) * 2008-09-22 2010-09-23 Biocept, Inc. Identification and isolation of fetal cells and nucleic acid
US8554579B2 (en) 2008-10-13 2013-10-08 Fht, Inc. Management, reporting and benchmarking of medication preparation
IT1391619B1 (en) 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
EP2364575B1 (en) * 2008-11-17 2016-01-27 Express Imaging Systems, LLC Electronic control to regulate power for solid-state lighting and methods thereof
PT2385992E (en) 2009-01-07 2015-04-16 Arcedi Biotech Aps Enrichment and identification of fetal cells in maternal blood and ligands for such use
WO2010099184A1 (en) * 2009-02-24 2010-09-02 Baylor College Of Medicine Antigenic approach to the detection and isolation of microparticles associated with fetal dna
WO2010106434A1 (en) 2009-03-17 2010-09-23 Silicon Biosystems S.P.A. Microfluidic device for isolation of cells
US8877028B2 (en) 2009-04-21 2014-11-04 The University Of British Columbia System and methods for detection of particles
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US20110312503A1 (en) 2010-01-23 2011-12-22 Artemis Health, Inc. Methods of fetal abnormality detection
US8774488B2 (en) 2010-03-11 2014-07-08 Cellscape Corporation Method and device for identification of nucleated red blood cells from a maternal blood sample
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
PT2638176T (en) 2010-11-09 2017-10-17 Arcedi Biotech Aps Enrichment and identification of fetal cells in maternal blood and ligands for such use
IT1403518B1 (en) 2010-12-22 2013-10-31 Silicon Biosystems Spa MICROFLUID DEVICE FOR PARTICLE HANDLING
SG192226A1 (en) * 2011-01-31 2013-09-30 Esoterix Genetic Lab Llc Methods for enriching microparticles or nucleic acids using binding molecules
JP6247218B2 (en) 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション Cancer biomarkers
ITTO20110990A1 (en) 2011-10-28 2013-04-29 Silicon Biosystems Spa METHOD AND APPARATUS FOR OPTICAL ANALYSIS OF LOW TEMPERATURE PARTICLES
ITBO20110766A1 (en) 2011-12-28 2013-06-29 Silicon Biosystems Spa DEVICES, EQUIPMENT, KITS AND METHOD FOR THE TREATMENT OF A BIOLOGICAL SAMPLE
WO2013104994A2 (en) 2012-01-13 2013-07-18 The University Of British Columbia Multiple arm apparatus and methods for separation of particles
PL2812431T3 (en) 2012-02-09 2020-02-28 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP2834376B1 (en) * 2012-04-06 2017-03-15 The Chinese University Of Hong Kong Noninvasive prenatal diagnosis of fetal trisomy by allelic ratio analysis using targeted massively parallel sequencing
EP2844773B1 (en) 2012-05-04 2017-08-16 Boreal Genomics Corp. Biomarker analysis using scodaphoresis
WO2013177206A2 (en) 2012-05-21 2013-11-28 Fluidigm Corporation Single-particle analysis of particle populations
CA2883273C (en) 2012-08-31 2023-10-24 Baxter Corporation Englewood Medication requisition fulfillment system and method
NZ716476A (en) 2012-10-26 2018-10-26 Baxter Corp Englewood Improved work station for medical dose preparation system
KR101695119B1 (en) 2012-10-26 2017-01-23 백스터 코포레이션 잉글우드 Improved image acquisition for medical dose preparation system
WO2014067528A1 (en) 2012-10-29 2014-05-08 Arcedi Biotech Aps Improved enrichment and detection of rare blood cells
US9340835B2 (en) 2013-03-15 2016-05-17 Boreal Genomics Corp. Method for separating homoduplexed and heteroduplexed nucleic acids
US9709556B2 (en) 2013-12-11 2017-07-18 Analiza, Inc. Devices and methods for determining and/or isolating circulating cancer cells
US20150160246A1 (en) 2013-12-11 2015-06-11 Analiza, Inc. Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells
JP2017525032A (en) 2014-06-30 2017-08-31 バクスター・コーポレーション・イングルウッドＢａｘｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｎｇｌｅｗｏｏｄ Managed medical information exchange
WO2016038929A1 (en) * 2014-09-11 2016-03-17 富士フイルム株式会社 Method for detecting presence/absence of fetal chromosomal aneuploidy
US11575673B2 (en) 2014-09-30 2023-02-07 Baxter Corporation Englewood Central user management in a distributed healthcare information management system
US11107574B2 (en) 2014-09-30 2021-08-31 Baxter Corporation Englewood Management of medication preparation with formulary management
EP3937116A1 (en) 2014-12-05 2022-01-12 Baxter Corporation Englewood Dose preparation data analytics
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
AU2016209521A1 (en) * 2015-01-23 2017-08-17 Unimed Biotech (Shanghai) Co., Ltd Microfluidics based fetal cell detection and isolation for non-invasive prenatal testing
JP2018507487A (en) 2015-03-03 2018-03-15 バクスター・コーポレーション・イングルウッドＢａｘｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｎｇｌｅｗｏｏｄ Pharmacy workflow management with alert integration
US11130986B2 (en) 2015-05-20 2021-09-28 Quantum-Si Incorporated Method for isolating target nucleic acid using heteroduplex binding proteins
CN104951671B (en) * 2015-06-10 2017-09-19 东莞博奥木华基因科技有限公司 The device of fetal chromosomal aneuploidy is detected based on single sample peripheral blood
CN116206744A (en) 2015-06-25 2023-06-02 甘布罗伦迪亚股份公司 Medical device systems and methods with distributed databases
CN108449994B (en) 2015-09-18 2021-10-01 贝勒医学院 Identification of immunogenic antigens from pathogens and correlation with clinical efficacy
CN109415697A (en) * 2016-04-07 2019-03-01 梅索泰克斯公司 Separate the method and its application of karyocyte and karyocyte group
AU2017381172A1 (en) 2016-12-21 2019-06-13 Gambro Lundia Ab Medical device system including information technology infrastructure having secure cluster domain supporting external domain
EP3575399A4 (en) * 2017-01-24 2020-01-08 BGI Shenzhen Exosomal dna-based method for performing non-invasive prenatal diagnosis and application thereof
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
CN110117571B (en) * 2019-05-08 2023-01-31 南方医科大学南方医院 Kit and method for non-invasively obtaining fetal rare cells
BR112021024474A2 (en) 2019-06-07 2022-01-18 Arcedi Biotech Aps Prenatal diagnosis method
ES2942363T3 (en) * 2019-08-14 2023-05-31 Bgi Genomics Co Ltd Method and device for determining the concentration of fetal nucleic acid in the blood of a pregnant woman
US11738288B2 (en) 2020-06-29 2023-08-29 Jacques Chammas Automated system and method to isolate specific cells from blood or bone marrow
CN112945667B (en) * 2021-02-01 2024-03-26 海南师范大学 Preparation method of blood single-cell suspension for removing nucleated red blood cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190535A (en) * 1978-02-27 1980-02-26 Corning Glass Works Means for separating lymphocytes and monocytes from anticoagulated blood
US4675286A (en) * 1985-01-28 1987-06-23 Aspen Diagnostics, Inc. Fetal cell separation and testing
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE68928535T2 (en) * 1988-12-06 1998-04-16 Flinders Technologies Pty Ltd ISOLATION OF FETAL CELLS FROM MATERNAL BLOOD FOR CARRYING OUT PRENATAL DIAGNOSTICS
US5641628A (en) * 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
EP0502037A1 (en) * 1989-11-24 1992-09-09 Isis Innovation Limited Prenatal genetic determination

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166555A1 (en) * 1999-11-10 2004-08-26 Rebecca Braff Cell sorting apparatus and methods for manipulating cells using the same
WO2002101387A3 (en) * 2001-06-08 2004-03-04 Consiglio Nazionale Ricerche A non invasive method for screening and diagnosis fetal aneuploidies
WO2002101387A2 (en) * 2001-06-08 2002-12-19 Consiglio Nazionale Delle Ricerche A non invasive method for screening and diagnosis fetal aneuploidies
US8372579B2 (en) 2002-09-27 2013-02-12 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US8895298B2 (en) 2002-09-27 2014-11-25 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US8304230B2 (en) 2002-09-27 2012-11-06 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US10081014B2 (en) 2002-09-27 2018-09-25 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US11052392B2 (en) 2002-09-27 2021-07-06 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US20070259424A1 (en) * 2002-09-27 2007-11-08 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US20070160503A1 (en) * 2003-06-13 2007-07-12 Palaniappan Sethu Microfluidic systems for size based removal of red blood cells and platelets from blood
US20100216153A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20100216151A1 (en) * 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US9956562B2 (en) 2005-04-05 2018-05-01 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US8021614B2 (en) 2005-04-05 2011-09-20 The General Hospital Corporation Devices and methods for enrichment and alteration of cells and other particles
US20070099207A1 (en) * 2005-04-05 2007-05-03 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8585971B2 (en) 2005-04-05 2013-11-19 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US20070026381A1 (en) * 2005-04-05 2007-02-01 Huang Lotien R Devices and methods for enrichment and alteration of cells and other particles
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US10786817B2 (en) 2005-04-05 2020-09-29 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090181421A1 (en) * 2005-07-29 2009-07-16 Ravi Kapur Diagnosis of fetal abnormalities using nucleated red blood cells
US20070026415A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026413A1 (en) * 2005-07-29 2007-02-01 Mehmet Toner Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026416A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026414A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070059719A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Business methods for prenatal Diagnosis
US20070059683A1 (en) * 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
US20070059781A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for size based separation and analysis
US20070059680A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for cell enrichment
US20070059774A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Kits for Prenatal Testing
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US11781187B2 (en) 2006-06-14 2023-10-10 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US10591391B2 (en) 2006-06-14 2020-03-17 Verinata Health, Inc. Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US11674176B2 (en) 2006-06-14 2023-06-13 Verinata Health, Inc Fetal aneuploidy detection by sequencing
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US10155984B2 (en) 2006-06-14 2018-12-18 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) * 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US10704090B2 (en) 2006-06-14 2020-07-07 Verinata Health, Inc. Fetal aneuploidy detection by sequencing
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US20090280492A1 (en) * 2006-06-14 2009-11-12 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20100291572A1 (en) * 2006-06-14 2010-11-18 Artemis Health, Inc. Fetal aneuploidy detection by sequencing
US20100196897A1 (en) * 2007-05-04 2010-08-05 Silicon Biosystems S.P.A. Method and Device for Non-Invasive Prenatal Diagnosis
US8383341B2 (en) * 2007-05-04 2013-02-26 Silicon Biosystems S.P.A. Method for non-invasive prenatal diagnosis
US20090317817A1 (en) * 2008-03-11 2009-12-24 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US8709726B2 (en) 2008-03-11 2014-04-29 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US10612086B2 (en) 2008-09-16 2020-04-07 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US20100105049A1 (en) * 2008-09-16 2010-04-29 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US20100273165A1 (en) * 2008-09-16 2010-10-28 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US10669585B2 (en) 2008-09-20 2020-06-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US20100112575A1 (en) * 2008-09-20 2010-05-06 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing
US20100304978A1 (en) * 2009-01-26 2010-12-02 David Xingfei Deng Methods and compositions for identifying a fetal cell
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
US11180799B2 (en) 2009-12-22 2021-11-23 Sequenom, Inc. Processes and kits for identifying aneuploidy
WO2011087760A3 (en) * 2009-12-22 2011-11-10 Sequenom, Inc. Processes and kits for identifying aneuploidy
US20110151610A1 (en) * 2009-12-23 2011-06-23 Varian Semiconductor Equipment Associates, Inc. Workpiece patterning with plasma sheath modulation
US9546392B2 (en) 2010-01-21 2017-01-17 Biocep Ltd. Magnetic separation of rare cells
US9217131B2 (en) 2010-01-21 2015-12-22 Biocep Ltd. Magnetic separation of rare cells
US8460872B2 (en) 2011-04-29 2013-06-11 Sequenom, Inc. Quantification of a minority nucleic acid species
US8455221B2 (en) 2011-04-29 2013-06-04 Sequenom, Inc. Quantification of a minority nucleic acid species
US8450061B2 (en) 2011-04-29 2013-05-28 Sequenom, Inc. Quantification of a minority nucleic acid species
US11004537B2 (en) 2011-06-24 2021-05-11 Sequenom, Inc. Methods and processes for non invasive assessment of a genetic variation
US10323268B2 (en) 2011-10-06 2019-06-18 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11560586B2 (en) 2011-10-06 2023-01-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11492659B2 (en) 2011-10-06 2022-11-08 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11437121B2 (en) 2011-10-06 2022-09-06 Sequenom, Inc. Methods and processes for non-invasive detection of a microduplication or a microdeletion with reduced sequence read count error
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
US11001884B2 (en) 2011-10-06 2021-05-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10424394B2 (en) 2011-10-06 2019-09-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11697849B2 (en) 2012-01-20 2023-07-11 Sequenom, Inc. Methods for non-invasive assessment of fetal genetic variations that factor experimental conditions
US10738359B2 (en) 2012-03-02 2020-08-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11312997B2 (en) 2012-03-02 2022-04-26 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US11306354B2 (en) 2012-05-21 2022-04-19 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US10482994B2 (en) 2012-10-04 2019-11-19 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10497462B2 (en) 2013-01-25 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US10930368B2 (en) 2013-04-03 2021-02-23 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11462298B2 (en) 2013-05-24 2022-10-04 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10699800B2 (en) 2013-05-24 2020-06-30 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10622094B2 (en) 2013-06-21 2020-04-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10964409B2 (en) 2013-10-04 2021-03-30 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11929146B2 (en) 2013-10-07 2024-03-12 Sequenom, Inc. Systems for non-invasive assessment of chromosome alterations using changes in subsequence mappability
US10438691B2 (en) 2013-10-07 2019-10-08 Sequenom, Inc. Non-invasive assessment of chromosome alterations using change in subsequence mappability
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11783911B2 (en) 2014-07-30 2023-10-10 Sequenom, Inc Methods and processes for non-invasive assessment of genetic variations
US11200963B2 (en) 2016-07-27 2021-12-14 Sequenom, Inc. Genetic copy number alteration classifications
US11694768B2 (en) 2017-01-24 2023-07-04 Sequenom, Inc. Methods and processes for assessment of genetic variations

Also Published As

Publication number Publication date
US20070015171A1 (en) 2007-01-18
US20060051775A1 (en) 2006-03-09
US20020137088A1 (en) 2002-09-26
US20040018509A1 (en) 2004-01-29
US20080182261A1 (en) 2008-07-31
US5641628A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
US5641628A (en) Non-invasive method for isolation and detection of fetal DNA
AU658132B2 (en) Non-invasive method for isolation and detection of fetal DNA
US5714325A (en) Prenatal diagnosis by isolation of fetal granulocytes from maternal blood
US5750339A (en) Methods for identifying fetal cells
Bianchi et al. Isolation of fetal DNA from nucleated erythrocytes in maternal blood.
Bianchi et al. Detection of fetal cells with 47, XY,+ 21 karyotype in maternal peripheral blood
Wachtel et al. Fetal cells in the maternal circulation: isolation by multiparameter flow cytometry and confirmation by polymerase chain reaction
Bianchi Prenatal diagnosis by analysis of fetal cells in maternal blood
US5437987A (en) Triple gradient process with antibody panning to recover nucleated fetal cells from maternal blood
Covone et al. Analysis of peripheral maternal blood samples for the presence of placenta‐derived cells using Y‐specific probes and McAb H315
Wessman et al. Fetal granulocytes in maternal venous blood detected by in situ hybridization
Simpson et al. Isolating fetal nucleated red blood cells from maternal blood: the Baylor experience—1995
JP2001502805A (en) Use of anti-embryonic hemoglobin antibodies to identify fetal cells
WO1995026417A1 (en) Culture and isolation of fetal cells from maternal peripheral blood
Goldberg Fetal cells in maternal circulation: progress in analysis of a rare event.
AU691040B2 (en) Enrichment of fetal cells from maternal blood
Orsetti et al. Fetal cells in maternal blood: the use of primed in situ (PRINS) labelling technique for fetal cell detection and sex assessment
Nagy et al. Isolation of epsilon‐haemoglobin‐chain positive fetal cells with micromanipulation for prenatal diagnosis
CA2068660C (en) Non-invasive method for isolation and detection of fetal dna
Cotteret et al. Fluorescent in situ hybridization on flow‐sorted cells as a tool for evaluating minimal residual disease or chimerism after allogeneic bone marrow transplantation
Bianchi Progress in the genetic analysis of fetal cells circulating in maternal blood
AU2004201022A1 (en) Non-invasive Method for Isolation and Detection of Fetal DNA
Koumantaki et al. Microsatellite analysis provides efficient confirmation of fetal trophoblast isolation from maternal circulation
AU9718698A (en) Prenatal diagnosis by isolation of fetal granulocytes from maternal blood
Dave et al. ARTICLE_TITLE

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION